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Extracellular vesicle (EV) research is a rapidly growing field, with renewed 
interest due in part to the discovery of the association of EVs with small extracellular 
RNAs (exRNA), in particular microRNAs. Roles of EVs and their RNA cargo in 
facilitating or fighting infection with viruses such as HIV-1 are likely but remain 
incompletely understood. To investigate one aspect through which EVs might play a role 
in infection, we first evaluated the EV and exRNA population of cervical-vaginal fluid in 
Asian macaques, initially in endometriosis and subsequently in animals with naturally 
suppressed SIV infections. Evaluating the miRNA cargo of EVs from infected animals 
relative to uninfected animals, we found that miR-186 was more abundant in the infected 
animals, suggesting it could be a potential restriction factor of SIV. We then used in vitro 
culture to establish the importance of EVs in HIV proliferation and maturation. We found 
that when EVs are removed from culture media, cell lines, either acutely or latently 
infected with HIV-1, experienced increased viral production. Virus produced by these 
cells was also more infectious than baseline. Restoration of cell-derived EVs to EV-
depleted cell culture rescued virus production to normal levels. Finally, we investigated 
miRNA expression in different blood T-cell subsets of HIV-1 elite suppressors (ES), for 
comparison with those of healthy (i.e. uninfected) controls (HC) and HIV-1 chronic 
progressors (CP). EVs and cell-free exRNAs have also been collected from all donors. 
We found that several miRNA species were differentially regulated in T-cell types in ES 
compared with HC or CP, consistent with previous studies examining PBMCs. 
Interestingly, we also found that the miRNA profile of different classes of cells, i.e., 
Naïve, Central Memory or Effector Memory, clustered together irrespective of CD4+ or 
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CD8+ phenotype in HC. These data taken together demonstrate the importance of EVs 
and their cargo in the context of retroviral infection and set the stage for future studies to 
further elucidate the complex relationship between HIV-1, miRNA and EVs. 
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History and treatment of HIV-1 
HIV-1, an enveloped, single-stranded RNA retrovirus, was first recognized as 
HTLV-III in 1983 and has developed into a global pandemic that currently remains 
without cure [1,2]. HIV-1 infected individuals, if left untreated, will eventually develop 
one of more defining conditions of acquired immune deficiency syndrome (AIDS). AIDS 
occurs after depletion of immune surveillance cells by HIV-1, cells which typically help 
to fight off common pathogens, leaving the infected individual susceptible to 
opportunistic infections. As of 2016, the current estimate of global infections was 36.7 
million individuals living with HIV; of these 36.9 million individuals, 20.9 million were 
receiving antiretroviral therapy [3]. Since the peak of the pandemic in 2005, with over 2 
million deaths in a single year alone, the new infection and death rates have steadily 
decreased. Yet, over 1 million individuals still die each year, indicating a significant 
remaining global impact [4]. While the development and implementation of 
combinatorial antiretroviral therapy (ART) has decreased morbidity and mortality rates, it 
does not represent a cure for HIV-1 infection, instead changing the nature of the disease 
to one of chronicity. Indeed, numerous non-AIDS-defining disorders associated with 
chronic inflammation and premature aging, such as HIV-associated neurocognitive 
disorders (HAND) now are prevalent in a large portion of the population whose viral 
loads are well suppressed [5,6]. Many of these disorders are incompletely understood and 
have no known therapies, which will continue to remain an issue as long as no cure for 
HIV-1 is developed. 
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A major obstacle for eradication of HIV-1 is the phenomenon of latency. Latent 
cells are long-lived, with integrated and quiescent HIV-1 DNA [7–10]. The best 
characterized latent reservoir of HIV-1 is the CD4+ T-lymphocyte, the cell preferentially 
infected by HIV-1 [11–13]. Importantly, when these latent cells are activated, a viral 
rebound is likely to result in novel infection of other cells. Just as in acutely infected 
cells, viral particles are formed by budding of cellular membranes of the host cell, 
incorporating viral nucleic acids and proteins. The released virion then undergoes a viral 
enzyme-driven maturation process, preparing the particle for infection of neighboring or 
distant cells. Importantly, the budding process relies on host cell machinery that is also 
used in the release of particles called extracellular vesicles (EVs), which play a role in 
intercellular messaging [14–17]. Could the similarities between viruses and EVs provide 
an avenue for development of novel therapy and potentially the eradication of HIV-1? 
 
Extracellular vesicles and HIV-1 
EVs are a heterogeneous population of mostly submicron bodies that have a 
double-leaflet membrane. EVs form by budding directly from the cell surface membrane 
(canonical “microvesicles” or “ectosomes”), while classically defined “exosomes” bud 
into the multivesicular body (MVB). This late endosome that releases its cargo, including 
exosomes, upon fusion with the plasma membrane. Considering that the retrovirion is 
itself a vesicle, EV studies have been ongoing in one form or another for over 80 years, 
with studies ranging from platelets to cartilage to antigen presentation [18–22]. Notably, 
a redoubled interest in the field began in 2007 with demonstration by Rataczak et al and 
Lötvall et al of transfer of RNA species directly associated with EVs [23,24]. It is now 
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known that EVs package a variety of biologically active materials, including enzymes, 
mRNAs, as well as both long non-coding RNAs (lncRNA) and microRNAs (miRNAs) 
[25–28], all of which have important biological functions, including in the immune 
response.  
As mentioned, EVs and retroviruses have overlapping phenotypes. The diameters 
of HIV-1 virions and EVs are comparable, and some have likened HIV to a “Trojan 
exosome”, evading host response by mimicking a host EV [29]. In addition, EVs express 
a wide range of proteins on their surfaces, including adhesion molecules and important 
immunological molecules such as Major Histocompatibility Complex (MHC) [30,31]. 
EVs can transmit genomic DNA of other viruses like Hepatitis C [32] and pegiviruses 
[33], and have been shown to contain important HIV molecules, like viral RNA [34] and 
other proteins including Gag [35] and Nef [36,37], but remain distinct from functional 
HIV-1 virions, as they do not appear capable of initiating a primary infection [38].  
The complexity of the relationship between EVs and HIV-1 extends beyond their 
physical similarities to function. EVs may enhance infection by activating CD4+ T-
lymphocytes, rendering them susceptible to HIV-1 infection [39,40], but can also have a 
protective effect, preventing HIV-1 from actively infecting other cells [41]. Just as HIV-1 
strains may have different cellular or receptor tropism, EVs may play different roles 
against infections based on their cell origin [42,43]. 
 
EVs and the cervicovaginal compartment 
EVs have been isolated from almost every bodily fluid, including semen [44], 
blood [45], urine [46] and saliva, among many others. In many biofluids, the EVs are 
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uncharacterized or poorly characterized, including those derived from the cervicovaginal 
compartment. This canal is a source of potential biomarkers, especially in cases of 
infectious disease [47], so a better understanding of its immune defense potential is 
warranted. This is especially true of HIV-1 and SIV infections, against which EVs have 
been reported to have innate defense properties [48]. One of the elements that may 
contribute to EV defense potency is the miRNA cargo. 
 
miRNAs and HIV-1 
microRNAs (miRNAs), first described in 1993, are ~22 nucleotide ncRNA 
molecules found ubitiquously in plants and animals. These small RNAs modulate 
expression of proteins within and between cells [49]. miRNAs function by binding to the 
untranslated region (3’ UTR) of mRNAs, changing protein levels by degradation 
(complete complementarity) or translational repression (partial complementarity) of 
target mRNA [50]. The majority of miRNAs are transcribed by RNA Polymerase II into 
their first form, a long primary miRNA (pri-miRNA) [51]. The sterics of the formed 
molecule result in a hairpin structure, which is recognized by the Drosh-DGCR8 complex 
[52]. While still in the nucleus of the cell, this complex cleaves the pri-miRNA into a 
precursor miRNA (pre-miRNA), isolating the hairpin structure. The pre-miRNA is 
subsequently shuttled to the cytoplasm by the nuclear exporter protein Exportin 5 [53]. 
The enzyme Dicer removes the loop of the pre-miRNA, leaving a duplex comprised of 
the former 5’ and 3’ arms of the precursor. Finally, one of the complementary strands is 
loaded into an Argonaute protein, part of a complex called the RNA-induced Silencing 
Complex (RISC) [54,55]. 
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Once loaded into the RISC complex, the complementarity of the seed sequence, 
located at the 5’ end of the miRNA, and a target RNA sequence is the key determinant of 
binding capability to the target and thus the efficacy of silencing of each miRNA. While 
there are thousands of miRNA species, whose functions have been implicated in 
processes ranging from tumor suppression [56] to antiviral therapy[57]. 
Studies of miRNA and HIV-1 range from profile comparisons to targeting studies 
to functional assays evaluating potential therapies [58–60]. Previous work in our lab 
evaluated miRNA profiles of peripheral blood mononuclear cells (PBMCs), of HIV-1 
elite suppressors (ES), people who naturally suppress HIV-1 copy numbers below a 
detectable threshold of 50 copies/mL of peripheral blood [61]. A more complete 
understanding of the ES phenomenon and their miRNA profile potentially represents a 
path to more effective therapy and even perhaps an avenue to eradication. The 
mechanism of control is assuredly multifactorial, but in-depth profiling of specific cell 




 The goal of this project was to investigate how EVs and miRNAs are involved in 
SIV and HIV-1 infection, with a focus on cellular miRNA expression in human patient 
samples. Chapter two of this thesis reports characterization of EVs and their cargo in the 
cervicovaginal compartment, first looking at EV abundance in a macaque with 
endometriosis and then evaluating EVs and extracellular RNA in cervicovaginal lavage 
(CVL) from Rhesus macaques infected with SIV. The results demonstrate the importance 
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of vesicles in homeostasis, highlighted by a significant decrease in both the animal with 
endometriosis and in the animals infected with SIV. Evaluation of the miRNA cargo in 
the infected animals revealed an upregulation of miR-186. Additional functional in vitro 
studies with synthetic miR-186 in monocyte-derived macrophages show that miR-186 
may behave as an HIV-1 restriction factor. These results underscore the importance of 
EVs and their cargo in viral defense and emphasize the diversity of the innate immune 
response and the importance anatomic location may play in facilitating 
immunoprotection. 
 Chapter three addresses the depletion of EVs from cell culture medium used for 
HIV-1 in vitro studies. While the importance of serum EVs in cell migration and growth 
is known, whether serum EVs play a role in HIV-1 infection in vitro was unclear. We 
report increases in HIV-1 production in certain EV-depleted conditions, along with, in 
some cases, cellular morphology changes and decreased cell viability. Add-back of EV-
enriched ultracentrifuge pellets reduced HIV-1 production almost to baseline. Primary 
cells appeared to be less sensitive to EV depletion, although ACH-2 and U1 latency 
models also produced more HIV-1 under EV-depleted conditions. Of particular 
importance, virus produced under processed serum conditions was more infectious. 
Finally, changes in cellular metabolism and gene expression were associated with EV-
depleted culture conditions. These findings indicated that EVs play a significant role in 
cell homeostasis and may protect against infection in vitro. Additional work is needed to 
elucidate mechanisms through which the infectivity of HIV-1 is altered by serum EV-
depletion.  
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 Chapter four covers miRNA expression in the context of HIV-1 elite suppression. 
Given the complexity of the ES phenotype, greater understanding of the miRNA 
phenotype of different T-cells that are known to play significant roles in killing HIV-1 
seemed warranted. This final chapter first presents a novel pipeline for T-cell subset 
isolation/characterization and then presents a specialized miRNA immunophenotype for 
6 subsets: CD4+ and CD8+ Naïve, Central Memory and Effector Memory cells in 
healthy individuals. Several patterns emerged, the most apparent being that each class of 
cell, i.e, Naïve, Central Memory or Effector Memory, has a unique miRNA profile and 
clusters with the profiles from other individuals regardless of HIV-1 infection status or 
CD4+ or CD8+ phenotype. The greatest expression differences in miRNA species were 
observed in Naïve cells, with large fold increases in expression of miR-9 and miR-21 in 
ES relative to healthy controls, and almost all expression differences upregulated in ES or 
Chronic Progressors relative to the controls. Additional notable findings included 
downregulation of miR-196b, -193b, -31 and -146b-3p in Chronic Progressors relative to 
ES, especially in CD4+ Effector Memory cells. This chapter suggests that miRNA 
expression is associated with innate antiviral cellular response and adds to knowledge of 














































Potential role of cervicovaginal extracellular particles in diagnosis of endometriosis 
 
The work presented in this chapter was published in BMC Veterinary Research in August 
















Endometriosis is a benign but debilitating disease of humans and other primates 
that affects the reproductive tract and has a reported incidence rate of up to 10% in 
females of reproductive age [62]. Generally, the term endometriosis is used to describe 
the condition in which endometrial cells (glands or stroma) develop ectopically, or 
outside of the uterine cavity [63]. Symptoms of endometriosis include chromic abdominal 
and pelvic pain, dysmenorrhea, as well as subfertility and likely eventual infertility 
[64,65]. Treatment protocols have not been standardized, but typically include surgical 
removal of ectopic tissue as well as removal of associated adhesions. 
The current gold standard for diagnosis of the disease combines laparoscopic 
evaluation and biopsy. In humans, endometriosis is thought to be prevalent for an average 
eight to eleven years before diagnosis [66] and multiple years after the appearance of 
symptoms [67,68]. Earlier detection would likely make surgical treatment more effective, 
afford individuals affected by the disease more options for treatment, and assist in the 
search for factors involved in pathogenesis. Indeed, the urgent need for early diagnosis 
was recognized well over a half-century ago [69]. 
Despite a burgeoning literature on the topic, as yet there is no consensus on early, 
non-invasive diagnosis methods. Diagnostic markers have been sought in peritoneal, 
follicular, and endometrial fluid, in urine, and in blood cells and cell-free fractions (see 
reviews [67,68,70–72]). Employment of ultrasound, MRI [73,74] and measurement of 
electrical resistance of dermal-visceral zones [75] have also been studied. Recently, 
attention has turned to circulating miRNAs, which have been reported as biomarkers of 
various diseases [76]. At least three published studies [77–79] have found an association 
	 13	
between endometriosis and differential regulation of specific miRNAs in circulation, 
although caution in interpretation has been urged due to estrogen sensitivity of some 
miRNAs [80]. Remarkably, there is no overlap of miRNA biomarkers reported in the 
different studies. Indeed, one of the studies reported differential expression of miR-16, 
which was elsewhere used as an invariant control. The lack of concordance between 
circulating miRNA biomarker studies has previously been reported for conditions 
including breast cancer [81,82], and may be due to the high non-specific background of 
miRNAs that are not associated with disease or are associated with many conditions [83]. 
Since miRNAs are protected in biofluids by various molecular carriers [84,85], it may be 
possible to achieve greater discrimination by focusing on extracellular particles, such as 
extracellular vesicles (EVs) that may be specifically released from cells [82]. 
EVs are lipid bilayer vesicles [30] that carry a varied cargo including nucleic 
acids, proteins, metabolites, and lipids. Release of EVs is thought to have a variety of 
functions, including disposal of harmful cellular contents and transmission of regulatory 
molecules in a form of intercellular communication. While determining levels of specific 
EV cargoes such as miRNAs may be useful in diagnosis, an initial study might yield 
results with even simpler measurements such as EV particle or EV protein concentration. 
Indeed, such measurements have previously achieved reported success in ovarian cancer 
[86].  
We hypothesized that a promising potential avenue for achieving early diagnosis 
of reproductive tract diseases including endometriosis might involve examination of total 
extracellular particles and EVs in cervicovaginal secretions. In this report, we examined 
particle concentration in total extracellular particle and EV-enriched ultracentrifuged 
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fractions from cervicovaginal swabs (CVS) and cervicovaginal lavage (CVL) from an 
individual with endometriosis. We compared these data with results obtained from 
reproductively normal nonhuman primates, observing apparent disease-associated 
differences in particle concentrations. To our knowledge, this is the first report of 




A nine-year-old female rhesus macaque (Macaca mulatta) with a history of a 
previous caesarian section presented with a large, firm uterine mass on abdominal and 
rectal palpation at routine semi-annual physical exam. All animal studies were approved 
by the Johns Hopkins University Institutional Animal Care and Use Committee and 
conducted in accordance with the Weatherall Report, the Guide for the Care and Use of 
Laboratory Animals, and the USDA Animal Welfare Act. Abdominal ultrasound revealed 
numerous cysts near the uterus. Fine needle aspirate of one of the cysts revealed dark red-
brown fluid that on cytology contained numerous degenerate red blood cells, foamy 
macrophages with hemosiderin, scattered neutrophils and lymphocytes as well as 
numerous clusters of endometrial-like cells (chocolate cyst) (Figure 1). A laparotomy was 
subsequently performed, which revealed extensive cyst formation localized to the 
ovaries; numerous adhesions extending from and between the reproductive tract and the 




On necropsy, the animal was in good postmortem condition and good body 
condition (BCS 3/5). The uterus was markedly thickened and nodular with a prominent 
“chocolate brown” cystic structures on the serosal ventral surface. Dissection between the 
uterus body, uterine horns, and ovaries was not possible due to the extensive adhesions 
(Figure 2). One ovary was grossly discernable and exhibited multiple simple cysts as well 
as a cyst containing “chocolate brown” material.  
Ovarian histology confirmed initial examination impressions of endometriosis: 
Transmurally disrupting and expanding the parenchyma of the bladder and uterus and 
also impacting the mesentery of the retroperitoneal space were multiple, unencapsulated, 
infiltrative islands of ectopic endometrial glands surrounded by densely cellular 
endometrial stromal tissue. The endometrial glands were lined by simple columnar 
epithelial cells with a moderate amount of clear to pale eosinophilic cytoplasm. The 
endometrial stroma was composed of spindle cells with indistinct cell borders, scant 
eosinophilic cytoplasm and an oval nucleus with finely stippled chromatin. Occasionally 
glands contained moderate numbers of macrophages, neutrophils, erythrocytes, and 
cellular debris. Within the retroperitoneal mesenteric adipose tissue, multifocal areas of 
hemorrhage, degenerate neutrophils, and necrotic debris is appreciated along with plump 
mature reactive fibroblasts (adhesions). The adjacent lymph node contained increased 
number of histiocytes, which often demonstrated erythrophagocytosis along with 





Assessment of extracellular particles in secretions 
Just prior to euthanasia, CVS and CVL were collected. Samples were collected 
with the aid of a vaginal speculum by either gently swabbing in the endocervical area 
with a sterile cottom swab or by lavaging the vaginal vault with a syringe filled with 3.0 
mililiters of 1X PBS, respectively. The total yield of CVL fluid was recorded. Swabs 
were immediately placed in two mL of 1X Dulbecco’s PBS and within thirty minutes of 
collection were swirled in a circular fashion within the PBS and then repeatedly pressed 
against the side of their respective 15 mililiter conicals to ensure optimal liberation of 
secretions; lavage fluid was collected into a 15 mililiter conical. Normal CVL samples 
were pooled by species prior to analysis. Both types of samples were centrifuged at 
1,000xg for 15 minutes to remove cells and large debris. Following this first spin, 
supernatant from each of the sample types was saved, diluted 1:10 with 1X phosphate 
buffered saline (PBS) and subjected to single particle tracking with a NanoSight NS-500a 
system. At least five 20-second videos were recorded of each sample at a camera setting 
of 14, and files were analyzed at a detection threshold of ten using NanoSight software 
version 2.2. 
Samples subsequently underwent high-speed ultracentrifugation (110,000xg for 
70 minutes at 4˚C) using a Sorvall Discovery 100SEb instrument and a Sorvall AH-650b 
swinging-bucket rotor (k-factor =53). After carefully pouring off supernatant, pellets 
were resuspended in 500 ul PBS using an optimized resuspension protocol. Both sets of 
samples were diluted at a ratio of 1:10 as well and observed using the same camera and 




Particle counts of samples from the endometriosis case were compared with CVL and 
CVS data obtained from four other individuals (two rhesus macaques and two pigtailed 
macaques, Macaca nemestrina) that had no notable reproductive tract history or 
pathology at necropsy, using the same protocols. Histologic examination of endometrial 
tissue from the 4 reproductively normal animals revealed that the animals were either in 
the proliferative phase (n=3) or early secretory (n=1) phase of the menstrual cycle, 
allowing for the best physiologic comparison with respect to the presence of endometrial 
cells observed in endometriosis [87–89]. 
Results 
After removal of cells and large debris from the CVS fluid by low-speed 
centrifugation, on average approximately 30-fold fewer extracellular particles were found 
in the endometriosis sample than in samples from reproductively healthy rhesus and 
pigtailed macaques (Figure 4A). In corresponding CVL samples, similar but less 
pronounced differences were obtained (Figure 4B). 
Stepped ultracentrifugation is the most widely used and accepted method for EV 
enrichment [90], although other particles may co-purify with EVs [90–94]. Following a 
standard ultracentrifugation protocol, the resulting EV-enriched particle population was 
approximately nine- to 13-fold more abundant in CVS samples from reproductively 
healthy animals than in the case of endometriosis (Figure 4C), and approximately ten- to 




Here, we report nanoparticle tracking analysis of extracellular particles including 
EVs in cervicovaginal samples associated with a verified case of an ongoing endometrial 
disease process. Notably, particle concentration was markedly decreased in the case of 
endometriosis as compared with reproductively healthy animals. Since results were 
obtained after the disease had taken its full course, it is unclear whether this approach 
could be used in diagnosis of early stage disease. In addition, we cannot be sure as to 
what is the precipitating factor behind this observed decrease. Perhaps due to cyclic 
irregularities, normal vaginal secretions are decreased. Regardless, our finding suggests 
that expanded studies of extracellular particles including EVs in endometriosis are 
warranted, and that particulate components of cervicovaginal secretions may provide a 
novel, minimally invasive diagnostic tool for reproductive tract disease. Carefully 
controlled studies are also needed to determine the possible association of menstrual 
cycle stage or pregnancy with abundance of cervicovaginal extracellular particles and the 
cellular source(s) of these particles, especially EVs. As other studies have demonstrated 
an increased susceptibility to infections of the reproductive tract during hormonal 
fluctuations, examining particle populations in concert with hormone levels would 
certainly provide additional insight into the functional capacity of the EVs [95,96]. 
Finally, investigation of the nucleic acid and protein cargo of extracellular particles and 




Figure 1. Cytology of fine needle aspirate obtained from abdominal mass. 
Characteristic hemosiderin-laden macrophages are noted along with a tight cluster of 
cells with dense, large nuclei and minimal cytoplasm, consistent with endometrial-like 
cells on a moderate background of erythrocytes. Diff-Quick stain (40X). 
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Figure 2. Abdominal Mass. Multiple, large cystic and blood-filled nodules were present 
in the abdominal cavity along with numerous fibrous adhesions (arrows). 
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Figure 3. Abdominal Wall. Numerous poorly organized and ectacic endometrial glands 








Figure 4. Pooled Data from Cervico-Vaginal Swabs and Cervico-Vaginal Lavage. 
NTA demonstrated a drop in particles per milliliter in pooled samples from two rhesus 
macaques (Rh) and two pig-tailed (Pt) macaques as compared to the number of particles 
observed in the animal with endometriosis. A and B compare CVS and CVL particles per 
milliliter at low-speed centrifugation (PRE UC) and C and D compare particles observed 
post-ultracentrifugation (POST UC). Asterisk in panel B: a software malfunction resulted 
in incomplete acquisition of data and loss of sample. Error bars for averages in CVS 
samples indicate standard deviation of readings across multiple animals and deviation 
























miRNA profiling of primate cervicovaginal lavage and extracellular vesicles reveals 
miR-186-5p as a potential retroviral restriction factor in macrophages 
 






The cervicovaginal canal is a potential source of biological markers in forensics 
investigations [97–100] and reproductive tract cancers [101] and infections [47]. 
Cervicovaginal secretions may be collected by swab, tampon, or other methods, or 
secretion components may be liberated by a buffered wash solution and collected as 
cervicovaginal lavage (CVL). Beyond utility as biomarkers, constituents of 
cervicovaginal secretions including proteins [102] and certain microbes [103] may have 
protective roles, for example in wound healing and against HIV-1 infection [104–111]. 
Secreted components may also change quantitatively or qualitatively during the 
menstrual cycle [112].  
Compared with secreted proteins and the microbiome, several components of 
cervicovaginal fluids are less well understood, including extracellular RNAs (exRNAs) 
and their carriers, such as extracellular vesicles (EVs) and ribonucleoprotein complexes 
(exRNPs). EVs are potential regulators of cell behavior in paracrine and endocrine 
fashion due to their reported abilities to transfer proteins, nucleic acids, sugars, and lipids 
between cells [113]. EVs comprise a wide array of double-leaflet membrane extracellular 
particles, including exosomes and microvesicles [114], and range in diameter from 30 nm 
to well over one micron (large oncosomes) [115]. EV macromolecular composition tends 
to reflect, but is not necessarily identical to, that of the cell of origin [116]. EVs have 
been isolated from most cells, as well as biological fluids [113,117], including 
cervicovaginal secretions of humans [48] and rhesus macaques [118]. 
microRNAs (miRNAs) are one of the most studied classes of exRNA. These noncoding 
RNAs average 22 nucleotides in length and, in some cases, fine-tune the expression of 
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target transcripts [119,120]. Released from cells by several routes, miRNAs are among 
the most frequently examined biomarker candidates in biofluids and are reported to be 
transmitted via EVs. miRNAs are found not only in EVs, but also in free Argonaute-
containing protein complexes; the latter may outnumber the former, at least in blood 
[85,121]. miRNAs are also highly conserved [120], and abundant species typically have 
100% identity in humans and nonhuman primates [122]. (For this reason, we will refer to 
hsa- (Homo sapiens) and mml- (Macaca mulatta) miRNAs without the species 
designation unless otherwise warranted by sequence disparity.) While miRNAs have 
been profiled in cervicovaginal secretions and menstrual blood, mostly in the forensics 
setting [100,123,124], their associations with EV and exRNP fractions require further 
study. A recent publication reported that EVs from healthy vaginal secretions inhibited 
HIV-1 infection [48]. Another report found that CVL EVs (styled “exosomes”) were 
present at higher concentrations in cervical cancer, and that two miRNAs were also 
upregulated [101]. Our laboratory described a reduction of CVL EVs in a severe 
endometriosis case compared with reproductively healthy primates [118]. However, our 
study, along with others, was limited by the absence of molecular profiling of EV cargo 
[118].  
Here, we performed targeted miRNA profiling of EV-enriched and -depleted 
fractions of CVL and vaginal secretions collected from healthy and retrovirus-infected 
rhesus macaques. We queried how CVL EVs and miRNAs are affected by the menstrual 
cycle, an important potential confounder of biomarker studies. Similarly, we assessed 
possible associations with simian immunodeficiency virus (SIV) infection. We report an 
association of miR-186 levels with SIV infection and find that this miRNA also appears 
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to act in an antiretroviral fashion in HIV infection of macrophages. These studies provide 
baseline information for easily accessed CVL markers including EVs and miRNAs that 




CVL and whole blood samples were collected weekly for five weeks from two 
uninfected (control) and four SIVmac251-infected (infected) rhesus macaques (Macaca 
mulatta) as previously described [118]. All macaques were negative for simian T-cell 
leukemia virus and simian type D retrovirus and were inoculated intravenously. Animals 
were sedated with ketamine at a dose of 7-10 mg/kg prior to all procedures. CVL was 
performed by washing the cervicovaginal cavity with 3 mL of phosphate buffered saline 
(PBS, Thermo Fisher Scientific, Waltham, MA, USA) directed into the cervicovaginal 
canal and re-aspirated using the same syringe. Materials and procedures for sample 
collection are depicted in Figure 8. Volumes of CVL yield across collection dates were 
documented in Table 1. Whole blood (3 mL) was collected by venipuncture into syringes 
containing acid citrate dextrose solution (ACD) (Sigma Aldrich, St. Louis, MO, USA). 
Study Approvals 
All animal studies were approved by the Johns Hopkins University Institutional 
Animal Care and Use Committee (IACUC) and conducted in accordance with the 
Weatherall Report, the Guide for the Care and Use of Laboratory Animals, and the 
USDA Animal Welfare Act. 
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Sample Processing 
Sample processing began within a maximum of 60 minutes of collection and 
utilized serial centrifugation steps to enrich EVs as described previously [125], based on 
a standard EV isolation protocol [126]. Specifically, fluids were centrifuged: (1) 1,000 × 
g for 15mins at 4°C in a tabletop centrifuge; (2) 10,000 × g for 20 mins at 4°C; and (3) 
110,000 × g for 2 hours at 4°C with a Sorvall Discovery SE ultracentrifuge (Thermo 
Fisher Scientific) with an AH-650 rotor (k factor: 53.0) (Figure 8B). Following each 
centrifugation step, most supernatant was removed, taking care not to disturb the pellet. 
After each step, supernatant was set aside for nanoparticle tracking analysis (NTA; 200 
µL), and RNA isolation (200 µL) following the second and third steps. The pellet was 
resuspended in 400 µL of PBS after each centrifugation step. After the final step, the 
remaining ultracentrifuged supernatant was concentrated to approximately 220 µL using 
Amicon Ultra-2 10 kDa molecular weight cutoff filters (Merck KGaA, Darmstadt, 
Germany). 200 µL of the concentrate was used for RNA isolation and the remainder was 
retained for NTA. All samples reserved for RNA isolation were mixed with 62.6 µL of 
RNA isolation buffer (Exiqon, Vedbaek, Denmark) containing three micrograms of 
glycogen and 5 pg of synthetic cel-miR-39 as previously described [127]. Processed 
samples were analyzed immediately or frozen at -80°C until further use. 
For plasma, whole blood was centrifuged at 800 × g for 10 mins at 25°C. 
Supernatant was centrifuged twice at 2,500 × g for 10 mins at 25°C. The resulting 




Levels of progesterone (P4) and estradiol-17b (E2) were measured in plasma 
samples shipped overnight on dry ice to the Endocrine Technology and Support Core Lab 
at the Oregon National Primate Research Center, Oregon Health and Science University.  
Nanoparticle Tracking Analysis 
Extracellular particle concentration was determined using a NanoSight NS500 
NTA system (Malvern, Worcestershire, UK). Cervicovaginal lavage samples were 
diluted as needed and specified in Table 2 to ensure optimal NTA analysis. At least five 
20-second videos were recorded for each sample at a camera setting of 12. Data were 
analyzed at a detection threshold of two using NanoSight software version 3.0. 
Western Blot 
Western blot was used to detect the presence of EV protein markers and the 
absence of calnexin (endoplasmic reticulum marker) in CVL and enriched CVL EVs. 
Because of low quantities, both CVL and enriched EVs were pooled as indicated in Table 
2. 20 µL of pooled samples were lysed with 5 µL 1:1 mixture of RIPA buffer (Cell 
Signaling Technology, Danvers, MA. Cat #: 9806S) and protease inhibitor (Santa Cruz 
Biotechnology, Dallas, TX. Cat #: sc29131). 8 µL of Laemmli 4X sample buffer 
(BioRad, Hercules, CA. Cat #:161-0747 Lot #: 64077737) was added per sample, and 30 
µL of each was loaded into a Criterion TGX 10% gel (BioRad, Hercules, CA. Cat #: 
5671034 Lot #: 64115589) after 5 mins of 95ºC incubation. The gel was electrophoresed 
by application of 100V for 100 mins. The proteins were then transferred to a PVDF 
membrane (BioRad, Hercules, CA), which was blocked with 5% milk (BioRad, Hercules, 
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CA. Cat #: 1706404. Lot #: 64047053) in PBS+0.1%Tween®20 (Sigma-Aldrich, St. 
Louis, MO Cat #: 274348 Lot #: MKBF5463V) for 1 hour. The membrane was 
subsequently incubated with mouse anti-human CD63 (BD Biosciences, San Jose, CA 
Cat #: 556019 Lot #: 6355939) and mouse monoclonal IgG_2b CD81 (Santa Cruz 
Biotechnology, Dallas, TX Cat #: 166029 Lot #: L1015) primary antibodies, at a 
concentration of 0.5 µg/mL for 1 h. After washing the membrane, it was incubated with a 
goat anti-mouse IgG-HRP secondary antibody (Santa Cruz Biotechnology, Dallas, TX 
Cat #: sc-2005 Lot #: B1616) at a 1:10,000 dilution for 1 h. The membrane was then 
incubated with a 1:1 mixture of SuperSignal West Pico Stable Peroxide solution and 
Luminol Enhancer solution (Thermo Scientific, Rockford, IL Cat #: 34080 Lot #: 
SD246944) for 5 min. The membrane was visualized on chemiluminescence film 
(Denville Scientific, Holliston, MA Cat #: E3018 Lot #:79608091) for up to 150 seconds. 
The second blot was done in a reducing environment using 10mM DTT (Promega, 
Madison, WI Cat #: P1171 Lot #: 0000198991). Same procedures were followed with 
rabbit anti-human TSG101 (Cat #: ab125011 Lot #:GR180132-14), rabbit anti-syntenin 
(Abcam, Cambridge, MA Cat #: ab133267 Lot #: GR89146-10), and rabbit anti-calnexin 
(Abcam, Cambridge, MA Cat #: ab22595 Lot #:GR243392-3) primary antibodies. 
Subsequent incubation with goat anti-rabbit IgG-HRP secondary antibody (Abcam, 
Cambridge, MA Cat #: sc-2204 Lot #: B2216). All antibodies were used at the same 






Gold grids were floated on 2% paraformaldehyde-fixed CVL–derived samples for 
two minutes, then negatively stained with uranyl acetate for 22 seconds. Grids were 
observed with a Hitachi 7600 transmission electron microscope in the Johns Hopkins 
Institute for Basic Biomedical Sciences Microscope Facility. 
Total RNA Isolation and Quality Control 
RNA isolation work flow is shown in Figure 8C. RNA lysis buffer was added into 
each sample as described above prior to freezing (-80 °C). Total RNA was isolated from 
thawed samples using the miRCURY RNA Isolation Kit-Biofluids (Exiqon) per 
manufacturer’s protocol with minor modifications as previously described (10). Total 
RNA was eluted with 50 µL RNase-free water and stored at -80°C. As quality control, 
expression levels of several small RNAs including snRNA U6, miR-16-5p, miR-223-3p, 
and the spiked-in synthetic cel-miR-39 were assessed by TaqMan miRNA assays 
(Applied Biosystems/ Life Technologies, Carlsbad, California, USA) [128].  
miRNA Profiling by TaqMan Low-Density Array 
A custom 48-feature TaqMan low-density array (TLDA) (11) was ordered from 
Thermo Fisher, with features chosen based on results of a human CVL pilot study (G. 
Hancock and K.W. Witwer, unpublished data). Stem-loop primer reverse transcription 
and pre-amplification steps were conducted using the manufacturer’s reagents as 
previously described [129] but with 14 cycles of pre-amplification. Real time quantitative 
PCR was performed with a QuantStudio 12K instrument (Johns Hopkins University 
DNA Analysis Facility). Data were collected using SDS software and Cq values 
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extracted with Expression Suite v1.0.4 (Thermo Fisher Scientific, Waltham, MA USA). 
Raw Cq values were adjusted by a factor determined from the geometric mean of 10 
relatively invariant miRNAs. The selection process for these invariant miRNAs was to 1) 
rank miRNAs by coefficient of variation; 2) remove miRNAs with high average Cq 
(>30), non-miRNAs, and those with low amplification score; 3) select the lowest-CV 
member of miRNA families (e.g., the 17/92 clusters); and 4) pick the top 10 remaining 
candidates by CV: let-7b-5p, -miR-21-5p , -27a-3p, -28-3p, -29a-3p, -30b-5p, -92a-3p, -
197-3p, -200c-3p, and -320a-3p. 
Individual RT-qPCR Assays 
Individual TaqMan miRNA qPCR assays were performed as previously described 
[129] for miRs-19a-3p (Thermo Fisher Assay ID #000395), -186-5p (Thermo Fisher 
Assay ID #002285), -451a-5p (Thermo Fisher Assay ID #001105) , -200c-3p (Thermo 
Fisher Assay ID #002300), -222-3p (Thermo Fisher Assay ID #002276), -193b-3p 
(Thermo Fisher Assay ID #002367), -181a-5p (Thermo Fisher Assay ID #000480), and -
125b-5p (Thermo Fisher Assay ID #00449). We also measured miR-375-3p (Thermo 
Fisher Assay ID #00564), which was not included on the array. Data were adjusted to 
Cqs of miR-16-5p and miR-19a-3p, but conclusions were robust to different 
normalization methods. 
Blood Cell Isolation and Monocyte-Derived Macrophage Culture 
Total PBMCs were obtained from freshly drawn blood from human donors under 
a Johns Hopkins University School of Medicine IRB-approved protocol (JHU IRB 
#CR00011400). Blood was mixed with 10% Acid Citrate Dextrose (ACD) (Sigma 
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Aldrich, St. Louis, MO Cat #: C3821 Lot #: SLBQ6570V) with gentle mixing by 
inversion. Within 15 minutes of draw, blood was diluted with equal volume of PBS+ 2% 
FBS, gently layered onto room temperature Ficoll (Biosciences AB, Uppsala, Sweden 
Cat #:17-1440-03 Lot #: 10253776) in Sepmate-50 tubes (STEMCELL Technologies, 
Vancouver, BC, Canada Cat #: 15450 Lot #: 06102016) and centrifuged for 10 minutes at 
1200 × g. Plasma and PBMC fractions were removed, washed in PBS+ 2% FBS, and 
pelleted at 300 × g for 8 minutes. Pellets from 5 tubes were combined by resuspension in 
10 mL RBC lysis buffer (4.15 g NH#Cl, 0.5 g KHCO(, 0.15 g EDTA in 450 mL H)O; pH 
adjusted to 7.2–7.3; volume adjusted to 500 mL and filter-sterilized); total volume was 
brought to 40 mL with RBC lysis buffer. After incubation at 37 °C for 5 mins, the 
suspension was centrifuged at 400 × g for 6 mins at room temperature. The cell pellet 
was resuspended in Macrophage Differentiation Medium with 20% FBS (MDM20) to a 
final concentration of 2´10, cells/mL. PBMCs were plated at 4×10, cells per well in 12-
well plates and cultured in MDM20 for 7 days. One half of the total volume of medium 
was replaced on day 3. On day 7, cells were washed 3 times with PBS to remove non-
adherent cells. The medium was replaced with Macrophage Differentiation Medium with 
10% serum (MDM10) and cultured overnight prior to transfection. 
 
miRNA Mimic Transfection  
Differentiated macrophages were transfected with 50 nM miRNA-186-5p using 
Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA Cat #: 11668-019 Lot 
#:1467572) diluted in OptiMEM Reduced Serum Medium (Gibco, Grand Island, NY Cat 
#: 31985-070 Lot #: 1762285). Controls included mock transfections and transfection of 
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50 nM siRNA oligo labeled with Alexa Fluor 555 (Invitrogen, Fredrick, MD Cat #: 
14750-100 Lot #: 1863892). Plates were incubated for 6 hours at 37 °C. After incubation, 
successful transfection was confirmed by examining uptake of labeled siRNA with an 
Eclipse TE200 inverted microscope (Nikon Instruments, Melville, NY). Transfection 
medium was removed. The plates were washed with PBS and refed with 2 mL fresh 
MDM10 medium.  
 
HIV Infection 
HIV-1 BaL stocks were generated from infected PM1 T-lymphocytic cells and 
stored at −80 °C. 24 hours after mimic or mock transfections, macrophages were infected 
with HIV BaL and incubated overnight (stock, 80 µg p24/mL, diluted to 200 ng p24/mL). 
At days 3, 6, and 9 post-infection, 500 µL supernatant was collected for p24 release 
assays and cells were lysed with 600 µL mirVana lysis buffer for subsequent RNA 
isolation and analysis.  
 
HIV p24 Antigen ELISA 
Supernatant samples were lysed with Triton-X at a final concentration of 1%. The 
DuPont HIV-1 p24 Core Profile ELISA kit (Perkin Elmer, Waltham, MA Cat #: 
NEK050B001KT Lot #: 990-17041) was used per manufacturer’s instructions to measure 





Total RNA Isolation 
Total RNA was isolated using the mirVana miRNA Isolation Kit per 
manufacturer’s protocol (Ambion, Vilnius, Lithuania Cat #: AM1560 Lot #: 1211082). 
Note that this procedure yields total RNA, not just small RNAs. After elution with 100 
µL RNase-free water, nucleic acid concentration was measured using a NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). RNA isolates were 
stored at -80 °C. 
 
HIV Gag RNA RT-qPCR 
Real-time one-step reverse transcription quantitative PCR was performed with the 
QuantiTect Virus Kit (Qiagen, Foster City, CA Cat #:211011 Lot #: 154030803). Each 25 
µl reaction mixture contained 15 µl of master mix containing HIV-1 RNA standard, 100 
µM of FAM dye and IBFQ quencher labeled Gag probe (5’ ATT ATC AGA AGG AGC 
CAC CCC ACA AGA 3’), 600 nM each of Gag1 forward primer (5’TCA GCC CAG 
AAG TAA TAC CCA TGT 3’) and Gag2 reverse primer (5’ CAC TGT GTT TAG CAT 
GGT GTT T 3’), nuclease-free water, and QuantiTect Virus RT mix, and 10 µL serial-
diluted standard or template RNA. No-template control and no reverse transcriptase 
controls were included. Linear standard curve was generated by plotting the log copy 
number versus the quantification cycle (C-) value. Log-transformed Gag copy number 





Macrophage Viability Assessment by MTT Cell Proliferation Assay 
5 mg 3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) 
(Vybrant MTT cell proliferation assay kit, Invitrogen, Eugene, OR Cat #: V13154 Lot #: 
1897699) was dissolved in 1mL of PBS and incubated in the dark for 20 mins. Dissolved 
MTT was then diluted in 12 mL of phenol red-free MDM10 medium. Macrophages in 12 
well plates were washed with 2 mL PBS. 1 mL of MTT/MDM10 medium was added to 
each well and incubated at 37 °C for 45 mins. 12 mL of 0.01N hydrochloric acid was 
added to dissolve SDS, and 1 mL acidified SDS solution was added to each well and 
mixed thoroughly until all formazan crystals were dissolved. Formazan quantification 
was performed using an iMark microplate absorbance reader (BioRad, Hercules, CA) 
with a 570 nm test wavelength. Data were expressed as mean absorbance value (OD) of 
duplicate samples plus standard error of the mean.  
 
Data analysis 
Data processing and analysis were conducted using tools from Microsoft Excel 
(geometric mean normalization), Apple Numbers, GraphPad Prism, the MultiExperiment 
Viewer, and R/BioConductor packages including pheatmap (http://CRAN.R-
project.org/package=pheatmap; quantile normalization, Euclidean distance, self-
organizing maps, self-organizing tree algorithms, k-means clustering). Figures and tables 
were prepared using R Studio, Microsoft Excel and Word, Apple Numbers and Keynote, 
GraphPad Prism, and Adobe Photoshop. 
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Data Availability and Rigor and Reproducibility 
Array data have been deposited with the Gene Expression Omnibus (GEO) [130] 
as GSE107856. Data in other formats are available upon request. To the extent that 
sample quantities would allow, the MISEV2014 recommendations for EV studies were 
followed [93,131], and the EV experiments have been registered with the EV-TRACK 




Abnormal menstrual cycle of SIV-infected macaques and ovulation-associated changes in 
CVL EV-enriched particles 
Plasma and CVL were collected from two control and four SIV-infected 
macaques over the course of five weeks (Figure 8). Abnormal cycling was observed for 
infected subjects (K. Mulka, et al, manuscript in preparation). By nanoparticle tracking 
analysis, CVL EV concentration increased during ovulation (Figure 1A). Transmission 
electron microscopy was performed for representative fractions of CVL, revealing 
bacteria and large particles in the 10,000 × g pellet (Figure 1B). The 100,000 x g pellet 
included apparent EVs up to 200 nm in diameter (Figure 1C). EV markers (shown: CD63 
and CD81) were confirmed by Western blot in samples from control and infected 
subjects (Figure 1D). Calnexin was found only in tissue samples (Figure 1E). 
Interestingly, neither TSG101 nor syntenin (considered to be luminal EV proteins) could 
be detected in the EV-enriched fractions of CVL (Figure 1E), potentially indicating a 
predominance of surface-released EVs over endosomal-origin exosomes in these 
preparations. 
 
TLDA reveals an extracellular miRNA profile of the cervicovaginal compartment 
Based upon preliminary findings from a study of human CVL (Hancock and 
Witwer, unpublished data), we designed a custom TaqMan low-density array (TLDA) to 
measure 47 miRNAs expected to be present in CVL, along with the snRNA U6. CVL 
from all subjects and at all time points was fractionated by stepped centrifugation to yield 
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a 10,000 x g pellet (10K pellet), a 100,000 x g pellet (UC pellet), and 100,000 x g 
supernatant (UC supernatant). Total RNA from all fractions was profiled by TLDA. Raw 
(Figure 2A), quantile normalized (Figure 2B), and geometric mean-adjusted Cq values 
(Figure 2C) were subjected to unsupervised hierarchical clustering. This clustering did 
not reveal broad miRNA profile differences associated with sample collection time, 
menstruation, or SIV infection. 
 
Distribution of miRNAs across CVL fractions 
Across the three examined CVL fractions (p10, p100, S100), the ten most 
abundant miRNAs (lowest Cq values) were miRs-223-3p, -203a-3p, -24-3p, -150-5p, -
146a-5p, -21-5p, -222-3p, -92a-3p, -17-5p, and -16-5p. The average normalized Cq value 
for each miRNA was greater (i.e., lower abundance) in the p100 than the s100 fraction 
(Figure 3A and inset), and indeed in p10 and p100 combined (Figure 3B), suggesting that 
most miRNA in CVL, as in various other body fluids, is found outside the EV-enriched 
fractions. Considering all fractions, the differences between the EV-enriched and EV-
depleted fractions were significant even after Bonferroni correction for all features except 
U6, miR-191-5p, and miR-451a-5p. On average, the s100 fraction contained 86.5% of the 
total miRNA from these three fractions. In the p10 fraction, the average miRNA was 
detected at 10.5% its level in the s100 fraction (SD=5.7%). miR-34a-5p had the lowest 
(5.9%) and miR-28-3p the highest (33.7%) abundance compared with s100. In the p100 
fraction, miRNAs were on average 5.6% (SD=2.4%) as abundant as in s100. The least 
represented in p100 was miR-27a-3p (2.3%), and the best represented was again miR-28-
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3p (13.4%). miRNA rank was significantly correlated across fractions, despite minor 
differences in order (Figure 3C). 
 
qPCR validation 
Individual stem loop RT/hydrolysis probe qPCR assays were used to verify 
TLDA results for miRs-19a-3p, -186-5p, -451a-5p, -200c-3p, -222-3p, -193b-3p, -181a-
5p, and -125b-5p. miR-375-3p (not included on the array), was also measured because of 
a reported association with goblet cells (12). Results of qPCR assays, adjusted by miR-
16-5p for each sample, are shown in Figure 4A. Figure 4B compares miRNA ranks (1-
11) by TLDA and individual qPCR, which are generally in concordance. Note that 
expression of red blood cell miRNA miR-451a-5p was low, suggesting minimal 
contamination from blood for most samples.  
 
miRNA association with retroviral infection status 
An association of miRNA abundance with infection status could yield novel 
biomarkers as well as clues to roles of miRNA in modulating infection. However, the 
small number of subjects in our study was a challenge. Nevertheless, by considering all 
subjects and time points together for both infected and uninfected subjects, microarray 
data suggested a slightly reduced abundance of miRs-186-5p, -222-3p, and -200c-3p in 
infected samples, while qPCR revealed differential abundance of miRs-186-5p, -375-3p, 
and -125b-5p. (Figure 5). miR-186-5p was thus identified by both techniques as 
potentially associated with retroviral infection. 
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miR-186-5p inhibits HIV p24 release by monocyte-derived macrophages.  
To assess a possible influence of miR-186-5p (“miR-186”) on retroviral 
replication, we introduced miR-186 mimic or control RNAs into monocyte-derived 
macrophages 24 hours before infection or not with HIV. At days 3, 6, and 9 post-
infection (dpi), we measured HIV release (capsid p24 protein in culture supernatant) and 
transcription (cellular Gag mRNA copy number). By p24 release, robust infection was 
observed by 3 dpi, and p24 counts increased by two-fold or more by 9 dpi (Figure 6A) for 
multiple replicate experiments with cells from three donors. Compared with infected, 
untreated controls, mock-transfected cells (not shown), and cells transfected with a 
negative control RNA (labeled with a fluorophore to assess transfection efficiency), miR-
186 transfection was associated with a significant decline of released p24 at all time 
points (ANOVA with Bonferroni correction) (Figure 6B-D). The negative control 
condition showed a suppressive trend that reached nominal significance at 9 dpi. 
However, miR-186-associated suppression was significantly greater at all time points. 
 
No consistent effect of miR-186 on HIV RNA abundance 
Using a gag qPCR/standard curve, we quantitated full-length HIV-1 transcript in 
cells from three donors. In cells from only one of three donors were fewer HIV-1 copies 
associated with miR-186 mimic transfection (Figure 7). Overall, there was no statistically 





Cervicovaginal lavage and CVL EVs and exRNPs, like EVs in the uterus 
[133,134], may offer information about the health of the reproductive tract as well as 
clues about factors that facilitate or block transmission of infectious agents. Proteomic 
analyses of human [135] and rhesus macaque [47] CVL have suggested a core proteome 
and a highly variable proteome that responds to changes in pregnancy status, 
menstruation, infection, and other stressors. However, exRNA and extracellular vesicle 
profiles are less understood in this compartment. Thus, the major finding of this study is 
further characterization of CVL fluid of primates, including extracellular vesicle and 
miRNA profiles. EVs could be liberated from vaginal secretions by lavage, and these 
EVs could be concentrated using a standard stepped centrifugation procedure, with 
enrichment of positive (membrane-associated) markers and apparent absence of a cellular 
negative control. Furthermore, both EV-replete and EV-depleted fractions of CVL 
contained abundant miRNA. 
As reported for other biological fluids [85,136], miRNA concentration was 
highest in the EV-depleted CVL fractions, not in EV-enriched ultracentrifuged pellets, 
consistent with packaging of most extracellular miRNA into exRNPs; the function, if 
any, of extracellular miRNAs in the cervicovaginal tract of healthy individuals remains to 
be determined. We observed minimal differences in extracellular miRNA profiles 
between SIV-infected and uninfected subjects or, most surprisingly, during the course of 
the menstrual cycle, suggesting a certain stability of extracellular miRNA in the 
compartment. Correlation of miRNA concentrations in EV-depleted and -replete fractions 
was also apparent. Based on relative abundance, miRNAs in EVs and exRNPs of CVL 
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are likely derived from epithelial cells (including goblet cells), and cells of the immune 
system (as suggested, e.g., by myeloid-enriched miR-223 and lymphocyte-enriched miR-
150) [137]. Of the most abundant miRNAs we identified, many have been ascribed 
tumor-suppressive roles in various types of cancer (14–19). Also, miR-223 and miR-150 
have been described as “anti-HIV” miRNAs [60] among a variety of reported 
antiretroviral sRNAs, both host and viral [144–149]. Given their relative abundance in 
the vaginal tract, a common site for HIV infection, these miRNAs may contribute to 
antiviral defenses.  
Along these lines, a second major finding of this study is a possible role for miR-
186 in anti-retroviral defense. In contrast with an early report of direct binding of host 
miRNAs to retroviral transcripts and subsequent suppression [60], it now appears that 
this mechanism of suppression is relatively uncommon [150], and that anti-HIV miRNAs 
may exert effects through control of host genes instead [e.g., [151]]. Our data also 
support the conclusion that reduction of HIV RNA levels is not the main mechanism for 
miR-186-mediated suppression of HIV release. 
We would like to emphasize several weaknesses of the study and opportunity for 
future research:  
1) We used stepped ultracentrifugation without density gradients because of the 
small sample volumes available. Although stepped ultracentrifugation remains a 
widely used method for EV enrichment [126,152], subsequent gradients or 
alternative isolation methods could be attempted with larger volume samples to 
increase purity in future. Possibly, our study overestimates the abundance of 
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miRNAs in CVL EVs, and differential packaging into EVs and exRNPs is 
masked by contamination of our EV preps with exRNPs.  
2) Our qPCR array approach and focus on miRNAs leaves room for additional 
work. While we are confident that our array captured most of the abundant 
miRNAs in CVL, sequencing short and longer RNAs could reveal additional 
markers. 
3) The small number of subjects and the absence of obvious menstrual cycle in 
infected subjects precludes strong conclusions about EV or miRNA associations 
with either infection or the menstrual cycle. For example, we did not observe the 
expected increase in miR-451a or other red blood cell-specific miRNAs during 
menstruation. However, since only two animals showed evidence of cycling, 
experiments with more subjects and larger sample volumes are needed.  
4) Our previous criticisms of miRNA functional studies [153] also apply to our 
work here. Additional work is needed to prove that miR-186 can regulate 
retroviral release at endogenous levels, that it is present in active RNPs [154], its 
interactions with host targets, and a mechanism for viral suppression. Finally, it is 
possible, but must be demonstrated, that miR-186 acts in a paracrine fashion via 
EV or exRNP shuttles.  
5) We have investigated the effects of miR-186 only in monocyte-derived 
macrophages. We chose to begin with this cell type because of the abundance of 
miR-223 and the known role of macrophages in the epithelium. Other cell types 
should also be investigated. 
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Overall, the results presented here support further development of CVL and its 







Figure 1. EVs are found in cervicovaginal lavage. A) Particle concentrations of CVL 
100,000 × g ultracentrifuge (UC) pellets (blue) monitored weekly over five weeks for two 
SIV-negative (“control”) and four SIV-infected subjects. Red arrows indicate 
estimatedtime of ovulation of animal. B and C) Transmission electron micrographs of 
CVL 10,000 × g pellet (B) and 100,000× g pellet (C) confirm presence of bacteria and 
EVs (B) and EV-like particles (C). Western blot: enrichment of CD63 and CD81 markers 
(D) and absence of ER marker calnexin (E) in pooled 10,000 and 10,000 × g pellet 
fractions. Vaginal tissue homogenate and dendritic cell 100,000 × g  pellet controls were 
also positive for CD63 and CD81. EV luminal markers syntenin and TSG101 were 
present in cellular but not putative EV samples. In subfigure D, two blots are shown, with 







Figure 2. miRNA profile of CVL fractions. Targeted miRNA profiles were determined 
by custom TaqMan low-density array (TLDA). Hierarchical clustering of samples and 
features (Pearson correlation, average linkage) of data: raw (A) or normalized by (B) 
quantiles or (C) a geometric mean approach as described in the methods. Abundance 
scale: red (high) to low (blue).  
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Figure 3. Relative abundance of miRNAs in centrifuged CVL fractions. A) Abundant 
miRNAs in descending order based on Cq values normalized to the geometric mean for 
each sample. Inset: average of all miRNAs in UC pellet and UC supernatant. Error bars: 
SEM. B) miRNAs in each fraction (10,000× g pellet=p10, 110,000 × g pellet=p100, 
110,000× g supernatant=S100) are significantly correlated (p<0.0001, Spearman). C) 
miRNA expression in EV-enriched fractions (p10, p100) as a percentage of total 
estimated expression (p10+p100+S100 by Cq) in ascending order, from miR-27a-3p 




Figure 4. miRNA qPCR validation. A) Stem-loop reverse transcription/qPCR 
validation of UC p100 samples, all subjects and time points (individual dots). B) Ranks 






Figure 5. miR-186-5p downregulation: SIV. A) By TLDA, miRs-186, -222, and -200c 
were significantly less abundant in the CVL p100 fraction of infected subjects, ** 
p < 0.01, *** p<0.001. B) By qPCR, miRs-186, -375, and -125b were significantly less 













Figure 6. miRNA-186-5p inhibits p24 release. Monocyte-derived macrophages from 
human donors were infected with HIV-1 BaL. A) p24 production increased >2 fold for all 
donors from 3 to 9 days post-infection (dpi), infected but otherwise untreated cells. B-D) 
Transfection of miR-186 mimic was associated with a decrease of p24 release compared 
with untransfected controls (NC) and control RNA mimic-transfected controls (RC); 
ns=not significant, * p<0.05, ** p<0.01, **** p<0.0001 (ANOVA followed by 
Bonferroni correction for multiple tests). Results were obtained from 8 to 11 replicate 






Figure 7. miRNA-186-5p mimic transfection inconsistently suppresses HIV-1 gag 
mRNA production. Apparent downregulation of gag mRNA (qPCR assay with standard 
curve) was observed in miR-186-transfected monocyte-derived macrophages from only 1 
of 3 donors compared with control RNA-transfected cells (RC). Overall, results were 























Figure 8. Specimen Collection and Sample Processing Workflow. A) Materials used 
to collect blood, cervicovaginal lavage (CVL) and vaginal swab (VS—not discussed 
here) samples. CVL was collected with a syringe containing 3 mL of PBS. PBS was 
injected into the vaginal cavity and then withdrawn into the same syringe. VS samples 
were obtained serially using two cotton applicators to swab the vaginal canal. Each swab 
was placed in 2mL of 1× PBS and the swab material was removed from the cotton by 
swirling in PBS and then pressing to the side of the conical. B) Stepped 
ultracentrifugation to enrich for extracellular vesicles (EVs). C) Workflow including 








Table 1. Recovered Volumes: CVL 
 
 





































Serum extracellular vesicle depletion processes affect release and infectivity of HIV-
1 in culture 
 

























Extracellular vesicles (EVs) are a diverse group of bilayer-membraned particles 
that include so-called “exosomes” (canonically defined as budding into multivesicular 
bodies (MVBs) and being released upon MVB fusion with the plasma membrane) and 
“microvesicles” (often described as blebbing directly from the plasma membrane) 
[113,155]. The mode diameter of EVs in circulation approximates that of retroviral 
particles [155], and EVs and retroviruses share many common features [29]. Indeed, HIV 
has been called a “Trojan exosome,” eluding the host immune responses in part by 
masquerading as an EV [29].  
The relationship between EVs and HIV-1 infection is an area of active study, with 
some contrasting findings. While several other viruses can replicate via viral genomes 
packaged into host EVs [156,157], HIV-1 does not appear to be capable of transmitting 
infection through this route [38]. However, EVs produced by HIV-1-infected cells 
contain fragments of viral RNA [158] and viral proteins such as Nef [159] and Gag [35] 
(although another study did not find Nef to be associated with EVs [160]). HIV infection 
may alter the number and size of EVs as well as the host microRNA and proteins 
contained in EVs, which in turn may have implications for immune activation and HIV-1 
pathogenesis [41,161–163]. In the setting of HIV-1 infection, EVs containing viral or 
host components may contribute to or exacerbate other conditions, such as HIV-1- or 
opiate-mediated neuron damage [164,165]. Whether specific EVs enhance or oppose HIV 
infection remains unclear and likely is context-dependent. EVs from HIV-infected cells 
can facilitate infection by several different mechanisms: by forming aggregates that 
include and deliver HIV-1 virions [166]; by activating CD4+ T lymphocytes, rendering 
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them permissive for HIV-1 infection [39,40,167]; and by activating latent HIV-1 
infection [168]. On the other hand, EVs from CD4+ T-cells can act as decoys to prevent 
infection of cells [41], while EVs derived from human semen appear to inhibit HIV-1 
replication and transmission [169,170].       
We previously showed that many cell types grow more slowly in media prepared 
with  serum that had been ultracentrifuged to remove EVs [171]. Serum EV depletion has 
been observed to alter cell migration [172], and macrophages become more 
proinflammatory when grown without serum EVs [173]. In general, we observed a slight 
but significant decline in replication and viability in EV-depleted conditions [171]. The 
magnitude of these effects was variable, and, notably, an astrocyte cell line (U87) did not 
appear to be affected. Adding isolated EVs back to the EV-depleted medium rescued cell 
growth, suggesting that the reduction in cell growth was in fact due to the depletion of 
EVs (although a role for EV-associated or otherwise co-purifying factors cannot be ruled 
out). We also found that the majority of the EVs that were internalized by cells, in a 
protein-dependent fashion, were targeted to lysosomes [171]. The identity of any specific 
growth-promoting factors contained in the EVs, such as RNA, proteins, or lipids, remains 
unknown, as does the extent to which these putative factors are involved in nutrition, 
signaling, and/or information exchange. 
Prompted by these findings, we sought to determine whether serum EVs might 
affect HIV-1 replication in vitro. We used serum depleted of EVs by two methods and 
examined the effects of media prepared with these sera on the growth and behavior of 
cells that are susceptible to or infected with HIV-1. We also assessed the influence of EV 
depletion on virus production and infectivity. Finally, possible cellular explanations for 
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these results were probed via RNA, miRNA and Gene Ontology analysis. We conclude 
that two separate serum EV depletion protocols have a profound effect on HIV-1 
replication and infection, and that EVs and/or closely associated or co-depleted factors 
tend to exert a virus-suppressive effect. 
 
Methods 
EV Depletion  
For “TF-UC-EVD” FBS or “UC-EVD” FBS, either Thermo Fisher whole FBS or 
other commercially available FBS was diluted 1:4 [126] with Dulbecco’s PBS or base 
culture medium and was centrifuged in a Beckman ultracentrifugation tube at 110,000 x g 
for 18 hours at 4˚C (AH-629 rotor, k factor=242). Supernatant was gently removed from 
the top down by pipette, avoiding disturbing the bottom of the tube, and used for 
preparation of EV-depleted media, which was then filtered through a 0.22 µm filter 
(Millex no. SLG5033SS). “TF-EVD” medium was prepared similarly, but with Thermo 
Fisher Gibco™ Exosome-Depleted FBS (ThermoFisher, USA, Catalog #  A2720801), 
depleted by the manufacturer using a proprietary method. “EVR” refers to EV replete 
medium. 
Single particle tracking analysis 
Extracellular particle concentration was measured using a NanoSight NS300 
(Malvern, Worcestershire, UK) equipped with a 532 nm laser or a NanoSight NS500 with 
a 405 nm laser. At least five 20 second videos were recorded of each sample at a camera 
setting of 10, and files were analyzed at a detection threshold of five using NanoSight 




Samples were lysed with RIPA buffer (ThermoFisher, #89900). Protein 
concentration was determined by bicinchonic acid assay. 100 ug of protein from each 
sample was loaded onto a Criterion 10% Tris-HCL gel (BioRad, Hercules, CA, cat 
#3451018) and electrophoresed. The proteins were then transferred to a PVDF membrane 
(BioRad, cat# 1620174) and blocked with 5% powdered milk (BioRad, cat #1706404) in 
Dulbecco’s PBS (ThermoFisher, cat# 14190250) +0.1%Tween®20 (Sigma-Aldrich, St. 
Louis, MO, cat # P9416) for 1 h. The membrane was subsequently incubated with 
mouse-anti-human CD63 primary antibody (BD, cat #556019), at a 1:1000 dilution for 1 
hour, and mouse-anti-human CD81 (Santa Cruz Biotechnology, cat# sc-166029), at a 
1:1000 dilution for 1 hour. After washing the membrane, it was incubated with a goat-
anti-mouse IgG-HRP secondary antibody (Santa Cruz Technology, cat #sc-2005) at a 
1:10,000 dilution for 1 h. The membrane was then incubated with a 1:1 mixture of 
SuperSignal West Pico Stable Peroxide solution (ThermoFisher, cat# 34080) and 
Luminol Enhancer solution (ThermoFisher, cat# 34080) for 5 min. The membrane was 
visualized on Amersham HyperfilmTM ECL chemiluminescence film (GE Life Sciences, 
PA, cat # 28906839). 
 
Cell culture 
Cell lines  
H9 and PM1 (both T-lymphocytic); chronically HIV-1-infected T-lymphocytic 
(ACH-2) and promonocytic (U1) cells; and TZM-bl and HEK-293T cells were obtained 
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from AIDS Reagent and ATCC. Cells were grown in complete RPMI medium (R10) 
prepared with EVR, UC-EVD, or TF-EVD FBS as well as 1 mM L-glutamine 
(ThermoFisher, MA, USA; Cat # 25030081), and 1 mg/mL Pen-Strep (ThermoFisher, 




Blood was obtained from healthy human donors under a university-approved 
protocol (JHU IRB # CR00011400). Within 15 minutes of draw, blood was diluted 
approximately 2:5 in PBS/5 mM ethylenediaminetetraacetic acid (EDTA)/2% EV-
depleted FBS, loaded over room temperature Ficoll (GE Healthcare Biosciences, MA, 
USA; Cat # 17-1440-03) in SepMateTM 50 mL tubes (StemCell, Vancouver, Canada; Cat 
# 85450), and centrifuged at 1200 x g for 10 minutes. The plasma/PBMC fraction was 
centrifuged at 300 x g for 8 minutes, and incubated in red blood cell lysis buffer (4.15 g 
NH4CL, 0.5 g KHCO3, 0.15 g EDTA in 450 mL H2O, adjusted pH 7.2-7.3, brought to 
500 mL and filter-sterlized)  at 37˚C for 10 minutes. For monocyte-derived macrophages 
(MDM), PBMC were pelleted at 400 x g for 6 minutes, resuspended in cell culture media, 
and plated at 107 cells per well in 6-well plates. Differentiation proceeded for seven days 
in the presence of macrophage colony stimulating factor (M-CSF) (R&D Systems, MN, 
USA; cat # 216-MC) as described previously [174]. 
 
CD4+ T-cells were isolated from PBMCs via EasySepTM Human Naïve CD4+ T 
cell Isolation Kit (Vancouver, CA; Cat # 19155) (2). Purity was determined by flow 
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cytometry on a BD Fortessa using a CD4+ antibody (Becton Dickinson, NJ, USA; Cat 
#562658). Interleukin-2 was added as a baseline stimulant at a concentration of 10 U/mL 
(Thermo Fisher, MA, USA #PHC0026). Cells were activated 24 hours after isolation 
with phytohemagglutinin (PHA) at a concentration of 5 ug/mL, diluted in culture medium 
(Sigma-Aldrich, MO, USA; Cat # 693839-1G). 
 
HIV-1 infection 
HIV-1 Rf and BAL stocks were generated from chronically infected H9 and PM1 
strains, respectively, and stored at -80˚C. For H9 and PM1 cultures, HIV.Rf and 
HIV.BAL were added at a concentration of 500 ng/mL (p24) and incubated at 37˚C for 4-
6 hours. Cells were then rinsed with PBS and spun twice at 400 x g for 5 minutes each. 
For primary macrophage cultures, HIV.BAL was added at a concentration of 200-250 
ng/mL (p24) and incubated overnight at 37˚C before rinsing twice with PBS.  
 
Cell Viability 
Cell viability was assessed using the Muse™ Cell Analyzer and the Muse™ 
Count and Viability Kit according to manufacturer's instructions (EMD Millipore, 
Billerica, MA, USA; Cat # MCH100102) or the WST-1 cell viability assay (Roche, IN, 
USA; Cat # 5015944001). The plates were mixed on an Orbital Shaker on setting 2 
(Bellco, NJ, USA; Cat # 7744-20220) at room temperature for 30 min and absorbance 
was measured at 630 nm using an iMark™ Microplate Absorbance Reader (Bio-rad, CA, 
US). MTT cell viability assay (Thermo Fisher MA, USA; cat # V-13154 ) was performed 
by incubating culture plates with MTT reagent for four hours at 37˚C, adding SDS lysis 
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buffer, and incubating for four hours to overnight at 37˚C. Absorbance was measured at 
570 nm with a plate reader as above. 
 
HIV-1 P24 Assay 
200 µl of cleared cell culture supernatant from all evaluated samples was set aside 
for p24 assays (Perkin Elmer, Holland, via ThermoFisher Cat # 50-905-0509) at 
appropriate dilutions and following the manufacturer’s protocol. p24 levels were 




Luciferase expression in TZM-bl, which contain a luciferase gene under the 
control of a retroviral LTR, was monitored following overnight exposure of cells to 
H9/HIV.Rf- or PM1/HIV.BAL-containing-media from infected cells. The luciferase 
assay was done according to the manufacturer’s protocol using the Luciferase Assay 
System (Cat # E1500; Promega, WI, USA) and was read on a Fluoroskan Ascent FL 
luminometer (ThermoFisher, MA, USA). 
 
Flow Cytometry 
 Cells were removed from plates with gentle pipetting, washed with 1 x PBS, and 
stained for 20 minutes at room temperature in the dark. All antibodies were from BD 
(CD4, ApC-Cy7 : Cat # 341095; CD18, FITC: Cat # 555923; CD106, PE: Cat # 555647; 
CD54, PE-Cy7: Cat # 559771; CD195, APC: 556903). Samples were washed with 2 ml 
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of 1x PBS once, spun at 400 x g for 5 minutes, and resuspended in 300 µl of PBS to 
remove excess antibodies. Using a BD LSRFortessa, PBMCs were gated on lymphocytes 
by forward and side scatter profiles. Data were analyzed using FlowJo software v10.1 
(FlowJo, OR, USA). 
 
EV add-back 
Pellets from ultracentrifuged FBS were re-suspended and added at 1/200th and 
1/50th of the re-suspension volume to separate wells containing EVR, UC-EVD or TF-
EVD-serum-containing media. These pellets were co-added with virus stock at the time 
of infection. 
 
RNA Isolation and Gene Expression Analysis  
HEK293T cells (5 x 105) were grown on a 10 cm dish for 24 hours. Medium was 
replaced with fresh media containing EVR or UC-EVD serum. Following 48 hours of 
growth, RNA was extracted using Trizol (Trizol Reagent, Invitrogen) according to 
manufacturer’s instructions. RNA integrity was assessed by Agilent Bioanalyzer RNA 
6000 Chip (Agilent, Santa Clara, CA), and 500 ng total RNA labeled according to the 
manufacturer’s instructions (Illumina TotalPrep RNA kit). Biotinylated aRNA (750 ng) 
was hybridized to Illumina Human HT12v4 bead arrays overnight, rinsed and incubated 
with streptavidin-conjugated Cy3.  Arrays were scanned at a resolution of 0.54 microns 
(Illumina iScan), and intensities were extracted from the scanned images using Illumina 
GenomeStudio software V2011.1. Data were normalized by Z-Score transformation and 
analyzed with DIANE 6.0, a spreadsheet-based microarray analysis program. Z-
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normalized data were analyzed with principal component analysis (PCA). Z-Scores for 
paired treatment groups were compared using the Z-Ratio statistic to determine gene 
expression changes within each comparison. Expression changes for individual genes 
were considered significant if they met four criteria: Z-Ratio above 1.5 or below -1.5; 
false detection rate (FDR) < 0.30; a P-value statistic for Z-Score replicability below 0.05; 
and mean background-corrected signal intensity greater than zero. Gene set analysis was 
performed using the open-source DAVID Functional Annotation. 
 
miRNA qPCR array 
Total RNA was harvested from ACH-2, U1, and MDM grown under the different 
conditions using the miRvana total RNA isolation protocol as previously described [61]. 
A custom TaqMan low density array was ordered from Thermo Fisher, containing qPCR 
assays for 47 common miRNAs and the snRNA U6. Reverse transcription (100 ng 
starting material for each condition), pre-amplification, TLDA card processing were done 
using Thermo Fisher/Life Technologies reagents per manufacturer’s protocol and as 
previously described [129]. Data were extracted and processed as previously described 
[129], except that normalization was performed to the geometric mean of ten miRNAs 
detected in all samples (miRs-24, 17, 30b, 106a, 142-3p, 92a, 146a, 342-3p, 21, and 16).  
Hierarchical clustering (Pearson, average linkage) and visualization was done with 
MultiExperiment Viewer (MeV) [175]. 
 
Seahorse Respiration assays 
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Macrophages were plated in a Seahorse 96-well plate and were differentiated for 
seven days (see above) in EVR and EVD media. Cells were washed three times with 
media that did not contain sodium bicarbonate. Following one hour of incubation in a 37 
degree incubator, mitochondrial activity was assessed using the Seahorse XF96 Analyzer 
(Seahorse Bioscience) [176] according to the manufacturer’s instructions. Briefly, 
oxygen consumption rate (OCR) was measured following sequential addition of 2 µM 
oligomycin, 1 µM FCCP, and 5 µM rotenone/antimycin A. 
 
Data availability 
Gene expression data and miRNA microarray data have been deposited with the 
Gene Expression Omnibus (GEO) under accessions GSE89067and GSE88838, 
respectively, part of the SuperSeries GSE89068 and BioProject PRJNA350212. Any 






EV depletion and effects on cell line viability and proliferation 
FBS was processed by dilution and overnight ultracentrifugation (“UC-EVD”) as 
previously described [126] or by a proprietary commercial process (ThermoFisher or 
“TF-EVD”). These sera and unmanipulated FBS (“replete,” EVR) were used to make cell 
culture media as described in Methods. Relative abundance of particles in replete or 
depleted conditions was assessed by NanoSight nanoparticle tracking analysis (Figure 
1A), revealing decreased particle concentration of approximately 60-70%, with the 
greatest particle decline in the TF-EVD condition. However, we would like to make two 
important points. First, the apparent efficacy of ultracentrifugation-based particle 
depletion varies in our hands by lot of serum, ultracentrifuge run, and nanoparticle 
tracking instrument/protocol, ranging from approximately 50-80%, while the TF-EVD 
process efficacy ranged from about 65-95% (Figure 2). Second, as the terminology 
indicates, single particle tracking does not distinguish EVs from other particles. In 
contrast, Western blot for EV markers CD63 and CD81 reveals that, while these markers 
are barely detected in unprocessed FBS, they are highly enriched in ultracentrifuge 
pellets, demonstrating EV depletion (Figure 1B). Similar results were obtained for 
TSG101 and CD9, but the ER marker calnexin, golgi marker GM130 and nucleus marker 
nucleoporin were not detected in the pelleted fraction (Figure 3). We conclude that both 
ultracentrifugation and the TF-EVD process significantly but variably deplete particles 
including EVs from FBS, and that the TF-EVD process appears to be more effective than 
ultracentrifugation. 
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Two T lymphocytic cell lines, H9 and PM1, were cultured in EVR, UC-EVD and 
TF-EVD media to assess the effect of EV-depleted serum on cell viability and growth. 
For all three conditions, WST-1 assay demonstrated small but significant (p<0.0001, 2-
way ANOVA with multiple comparisons) differences in cell proliferation at Days 2, 3, 4 
post initial culture conditions (Figure 1C, D) consistent with previous reports (23). 
Similar results were obtained by measurement of cytotoxicity by means of an LDH assay 
(Figure 4). However, primary CD4+ T-cells and macrophages displayed minimal 
differences in metabolic activity when grown in TF-EVD media compared to replete 
conditions, as measured by MTT assay (Figure 1 E, F). 
 
Cells maintained in EV-depleted cell culture media exhibit increased HIV-1 production  
T-lymphocytic H9 and PM1 cell lines cultured for seven days under the three 
conditions were infected with HIV-1.Rf and HIV-1.BAL respectively. Morphologic and 
behavior differences were observed in the TF-EVD condition when compared with the 
EV replete condition. Specifically, cells in TF-EVD medium tended to cluster and form 
syncytia (Figure 5D, H) more frequently than cells in EVR medium (5C, G). Minimal 
morphologic differences between the two media types were seen in control, uninfected 
H9 and PM1 cells (Figure 5A,B and E, F). Cells in UC-EVD medium were of 
intermediate phenotype that varied considerably by production lot of UC-EVD FBS, 
consistent with the variable and less efficient particle depletion by UC that we observed. 
Unexpectedly, HIV-1 release, as measured by p24 ELISA, was significantly increased in 
the TF-EVD condition in both H9 and PM1 cells (Figure 3A, B). Increased HIV-1 
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production was also observed from CD4+ T-cells and MDM infected with HIV-1.Rf and 
HIV-1.BAL strains, respectively (Figure 6C, 3D, 7). 
 
EV add-back restores HIV-1 production to baseline levels in cells cultured in TF-EVD 
media 
To confirm that depleted material enriched in EVs contributes to the observed 
effects, resuspended EV-enriched UC pellets were added back to TF-EVD culture 
conditions. Irrespective of dose down to a 20% add-back, virus production was restored 
to levels significantly below the TF-EVD conditions (for example, HIV-1.Rf-infected H9 
cells, Figure 6E). That virus production was not restored completely to baseline may be  
consistent with reports that UC-pelleted EVs may tend to aggregate and lose functionality 
[177–179].  
 
EV-depleted cell culture conditions reverse HIV-1 latency 
ACH2 and U1 cells—models of HIV-1 latency in T-cells and monocytes, 
respectively—were cultured in replete medium and TF-EVD medium conditions. 
Significant differences in p24 production were observed in the TF-EVD condition as 
compared with the replete medium condition for both U1 and ACH2 cells in three 
experiments (Figure 8A, B)). Cell density was correspondingly reduced after day one in 
both cell types (TF-EVD medium, Figure 8C, D). Of potential interest, the U1 cells were 
the most sensitive to depleted conditions of any cell type we studied. Nevertheless, the 
minority of live cells appeared to continue releasing relatively large quantities of p24. We 
do not think this p24 detection is simply the result of release from dead cells, as analysis 
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of the cell lysate in PM1, U1 and ACH2 cell lines was lower or on par with the p24 
expression in the supernatant (Figures 9, 10E,F).   
 
Heightened infectivity of viruses produced under depleted cell culture conditions 
HIV-1 produced under depleted conditions was collected from H9 and PM1 cells 
and placed in p24-normalized amounts onto TZM-bl reporter cells, which encode a 
luciferase gene under the control of the HIV-1 LTR. Virus from TF-EVD conditions 
produced significant increases in luciferase expression that were at least two-fold higher 
when compared with virus produced under EVR source serum conditions for many tested 
concentrations of virus (Figure 11A-D, 12). Similarly, when virus grown in replete 
conditions was added to TZM-bl cells raised in either TF-EVD Source-based media or 
TF-EVD media, significant differences in luciferase expression were appreciated at 
higher concentrations of viral input for both HIV-1.BAL and HIV-1.RF (Figure 11E, F). 
 
Assessing functional differences of cell lines raised in EVD conditions 
To gather evidence for cellular changes that might possibly explain the observed 
responses to EV depletion, we performed several tests, including flow cytometry, 
respiration assays, miRNA qPCR array, and gene array.  
 
Flow cytometry: cell surface proteins 
The cell clumping observed in H9 cell cultures under EVD conditions prompted 
us to examine expression of several adhesion molecules and HIV-1 receptors by flow 
cytometry. Indeed, among other differences, VCAM-1 (CD106) and CCR5 expression 
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were found to be increased on H9 and PM1 cells cultured in EV-depleted conditions 
(Figure 13A, B). 
 
Respiration assay 
We next used the Seahorse Respiration assay to test respiration under EV-
depleted conditions (Figure 13C). There was a significant, multiple-fold decrease in basal 
and maximal respiration, as well as compromised ATP production in mitochondria of 
MDM grown with EV-depleted media (Figure 13D). This reduction in mitochondrial 
respiration is in agreement with our previous and current observations of reduced cell 
growth.  
 
miRNA qPCR array 
Certain cellular microRNAs (miRNAs) have been reported to control retroviral 
replication [60,145], while exogenous RNAs in cell culture medium are said to be taken 
up by cells [180]. We hypothesized that miRNA levels in cultured cells might be 
augmented by serum EV miRNAs, and that EV depletion might also indirectly affect 
miRNA expression. Either circumstance could result in reduced abundance of anti-HIV 
miRNAs, explaining an increase in HIV-1 production. However, results from miRNA 
profiling by a custom TaqMan low density array (TLDA) revealed no consistent changes 
in miRNAs across three cell types maintained in the different types of media. Unbiased 
hierarchical clustering showed cell type-specific miRNA expression patterns, but no 
indication of consistent differences associated with EVD conditions (Figure 14A). A total 
of five miRNAs appeared to be less abundant by 2-fold or more in one cell type under 
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EV-depleted conditions (one in MDM, three in U1, one in ACH2), but no miRNA was 2-
fold downregulated in more than one cell type, as one would expect if serum were an 
important and consistent source of miRNAs (Figure 14B). Importantly, previously 
reported anti-HIV miRNAs, including miRs-28-3p, -29a, -125b, -150, and -223, were not 
consistently diminished under EVD conditions. Similarly, there were no consistently 
upregulated miRNAs during EV depletion. 
 
Gene expression and lipidomics  
Gene array analysis was performed with cells grown in EVR and EVD conditions. 
Gene ontology analysis of genes that were at least 2.5-fold more abundant in cells grown 
with EVD media revealed a significant increase in transcripts associated with lipid 
synthesis pathways, and especially sterol biosynthesis pathways (Table 1). It was 
previously reported that EVs contain a high proportion of cholesterol, sphingomyelin and 
ceramide; therefore, the increase in their biosynthesis may be a compensation response to 





We show here the significant impact of serum EV depletion protocols on virus 
production by HIV-1 susceptible cells. Additionally, HIV-1 latency models undergo a 
degree of viral activation under EVD conditions. Effects of EV depletion were less 
pronounced in primary cells, but we did observe an impact on HIV-1 production by 
primary macrophages. Altogether, our findings suggest that EVs can inhibit HIV-1 
infectivity and release from leukocytes, and point to alterations in cellular lipids as a 
possible underlying mechanism.   
Greater HIV production could be achieved through higher rates of infection (i.e., 
involving viral life cycle steps from cell binding through integration). The finding that 
certain cell adhesion molecules, including HIV-1 receptors and co-receptors, are 
upregulated on cells in EVD conditions might be consistent with more efficient infection. 
It could also explain the greater aggregation and syncytium formation we found in H9 
cell culture. However, the observation that latency models are also affected by EVD 
conditions suggests that infection is not the sole explanation for our findings. 
Additionally, our EV add-back experiments—in which EV-enriched ultracentrifuge 
pellets were re-introduced into the proprietarily-depleted medium simultaneously with 
virus exposure—suggest that any cellular responses to the absence of EVs would have 
been reversed rapidly, perhaps too rapidly to invoke receptor involvement. Alternatively, 
virion interactions with EVs or lipids that were added back could have inhibited infection 
(although this seems inconsistent with previous findings [181]. It is also apparent that 
circulating or EV-bound miRNA are not changing due to the depletion process and thus 
are not a likely explanation for the observed cellular responses. 
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Gene ontology data, however, suggest another mechanism whereby virus 
production could be increased: in the relative absence of EVs, lipids involved in EV (and 
thus virion) biogenesis are upregulated. This may occur as the cell strives to achieve a 
homeostasis of membrane components, which must be sensed in some fashion. 
According to this hypothesis, normal interactions with diverse, non-self EVs or other 
lipid particles such as those found in serum preps could be viewed as a “security blanket” 
or a constant source of nutrition. In EV depletion, the cell might release its own EVs but 
be unable to make up for the presence of foreign entities. This is highly feasible, as 
culture media tend to contain much lower amounts of EVs than unprocessed serum. The 
observed surface upregulation of adhesion receptors is also consistent with this idea, 
bringing cells into closer contact with other membranes (cellular or EV). Notably, the 
sterol upregulation scenario would imply that the upregulation of HIV release is non-
specific, or specific only to the extent that virions bud from sterol-rich membrane 
microdomains. To delve further into these possibilities, more information is needed on 
how cells sense the presence of EVs: through molecules of or on the EV surface, the cell 
surface, or both. One might also anticipate experiments to investigate the contribution of 
EVs from different cellular sources, which could explain the reviewed the differing 
findings in the literature reviewed previously. 
Our latency model results are perhaps most exciting, suggesting that EV depletion 
could inform new strategies in HIV-1 eradication therapy. Depleting bulk EVs from 
plasma in vivo to increase HIV-1 production from latent cells in an eradication effort—in 
an approach analogous to leukapheresis—would be a difficult task. Even if such 
depletion were feasible, the same would likely be impossible in tissue. However, it might 
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be possible through pharmacologic means to block cells from sensing the presence of 
EVs. Clearly, more knowledge about the system is needed to assess and develop this 
possibility. 
As a final note, we would like to draw attention to an important caveat of this 
study. Although we concentrate here, in our language and experiments, on the effects of 
EVs, we hope that we have adequately conveyed that other interpretations are possible. 
The most accurate description of our results might be that putative EV depletion 
processes are associate with the observed effects. By extension, one might assume that 
EVs are involved, and this seems a reasonable assumption, given that we observed EV 
depletion by ultracentrifugation and by the commercial process, and the reversal of our 
findings during EV add-back. However, we cannot rule out that ultracentrifugation and 
other EV depletion protocols also deplete other components of serum.  A recent 
publication from the Buzás lab found extensive low density lipoprotein contamination of 
EV preparations, and that LDL particles decorate EVs after co-incubation [182]. It is 
possible that LDL, other lipoprotein particles, and protein aggregates contribute to the 
phenomena we report here. We hope that others will join us in pursuing the many 






Figure 1. EVD conditions affect cell culture proliferation. A) NTA of 25% FBS, 25% 
TF “source” FBS, UC-EVD of 25% commercial FBS, UC-EVD of 25% TF-Source FBS, 
and TF-EVD FBS and shows depletion of approximately 60% of particles by UC for both 
FBS types and the greatest depletion in TF-EVD FBS when compared with TF source 
FBS. Error bars represent standard deviation of 4 independent readings. **** p<0.005, 
one-way ANOVA with Tukey’s multiple comparison test. B) Western Blot analysis of 
25% TF source FBS (1), 25% Commerical FBS (2), TF-EVD FBS (3), UC-EVD of 25% 
TF-Source FBS (4), UC-EVD 25% commercial FBS (5), and the UC pellet of TF Source 
FBS (6) and commercial FBS (7) , and shows significant extraction of particles 
containing CD63 (MW ~ 30-65 kDa) and CD81 (MW ~22-25 kDa). All lanes were 
loaded with 100ug of protein. C) For H9 cells, WST-1 assay optical density was greatest 
at all time points for the replete media conditions. D) PM1 cells: results similar to H9 
cells. *=p<.005, difference between Replete and UC-EVD only; ** = p<0.005, 
differences between EVR and UC-EVD, UC-EVD and TF-EVD only; *** = p<.005, 
differences between EVR and UC-EVD and EVR and TF-EVD media; **** = p<.005, 
all types of media different from each other; Two-way ANOVA with multiple 
comparisons, six biological replicates measured E) No significant differences in cell 
viability observed in CD4+ T-cells or monocyte-derived macrophages cultured in UC-




Figure 2. UC-EVD serum (n=23) has an overall lesser and wider range of particle 
reduction than the observed in TF-EVD serum (n=5) by NTA assessment. A range of 
70-77% reduction is observed for TF-EVD method compared to a range of 41-62% in 






































Figure 3. Western Blot Verification. A) Western Blot for TSG101 (~49kDa) and 
CD9(~24kDa) shows high presence of markers in UC pellets of both TF-Source FBS and 
in-house FBS (lanes 6, 7) compared to the source and depleted FBS (Lanes 1-5), 
indicating significant removal of EVs. UC pellets (lanes 1, 2) examined for GM130 
(~130kDa), Nucleoporin (~53kDa) and calnexin (~80kDa) (B, C) demonstrated no 
presence of protein, indicating no significant cellular contamination from FBS source 
material. These proteins were also not observed in the FBS itself (lanes 5-7) or the UC-
EVD media (lanes 3,4). All lanes were loaded with 100ug of protein. 













Figure 4. Cell Viability Data. LDH assay of uninfected H9 and PM1 cells grown in 
replete, UC-EVD and TF-EVD conditions after 3 days of incubation shows small 




Figure 5. EVD serum affects cell morphology of cells infected with HIV-1. Marked 
aggregation and syncytium formation was observed in extended culture of HIV-1 
infected H9 T-cell line under EVD conditions compared with EVR conditions and with 
uninfected controls grown in both replete and depleted conditions  Extended culture of 
uninfected PM1 cells in replete and depleted media shows no differences in cell 
morphology, while similar phenotype changes as observed in H9 cells are noted between 


































Figure 6. EVD serum increases p24 production in multiple cell types, while add-
back of UC-derived pellet rescuses cells A) HIV-1.Rf  production in H9 cells is 
increased significantly in TF-EVD conditions by day 4. ****=p<.0001, 2 sample t-test 
with Holm-Sidak correction of three biological repeats B) By Day 4 post infection, 
HIV.BAL production in PM1 cells grown in TF-EVD conditions is significantly higher 
when compared with EVR medium. ****: p<.0001; 2 sample t-test, Holm-Sidak multiple 
comparison correction. Representative experiment of at least 3 biological replicates of 
CD4+ T-cells infected with HIV-1.Rf (C) and three independent experiments of at least 3 
biological replicates of monocyte-derived macrophages (MDM) infected with HIV-
1.BAL (D) show a modest increase in virus production when grown in TF-EVD medium. 
E) Addition of previously removed EVs to TF-EVD medium reduces p24 production 
back to near the EVR medium baseline in H9 cells. EVs isolated from stock FBS were 
added back to TF-EVD medium at 80% and 20% of their original concentrations. 
Supernatant was collected 1, 2, and 3 days post HIV-1.Rf infection. Measurements of 
virus release by p24 concentration at day 3 showed a pronounced difference between TF-
EVD conditions and all others, ****=p<0.001, one-way ANOVA, Tukey’s multiple 
comparison test of 3 biological repeats in one independent experiment.  
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Figure 7. Individual experiments from Figure 3D, showing donor-donor variability 
of p24 production. All experiments contain at least 5 biological replicates. For all 
graphs, ****=p>.0001, two-way ANOVA with Sidak’s multiple comparison test.  
 
 




































































Figure 8. EVD serum reverses latency in two latency model cell lines. A,B) Four 
independent experiments confirm higher p24 production in both ACH2 and U1 cells 
grown in TF-EVD conditions compared to replete conditions. *=p<.05, **=p<.005, 
***=p<.0005, two-way ANOVA with Sidak’s multiple comparisons test. C, D) 
Representative cell density data for U1 and ACH-2 cells from a single experiment. E) 
Representative data from a single experiment shows supernatant and pellet from U1 cells 
pellet has a much higher p24 production in TF-EVD conditions when compared to replete 
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Figure 9. p24 concentration in supernatant is significantly higher than cell lysate in 
infected PM1 cells grown in replete conditions. ****=p<0.001, **=p<.01, 2-way 
ANOVA with Sidak’s multiple comparison test of a single independent experiment with 
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Figure 10. Three independent experiments demonstrating decrease in luciferase 
expression. Experiments contain at least 3 biological replicates and demonstrate that 
luciferase expression in TZM/BL cells infected either with HIV.BAL (A-C) or HIV.RF 
(D-F) harvested from cells cultured with TF-EVD serum show variance in RLU from 
experiment to experiment, but show constant increase in relative infectivity of virus used 
for all experiments with 100ng and 50 ng of p24 input. Other inputs show a similar trend 
but are not significant across all experiments. ****=p<0.001, ***=p<.005, **=p<.01, 





Figure 11. EVD serum affects virus infectivity. A, B) Representative experiments 
demonstrating that EV-depleted media produce virus with comparatively greater 
infectivity. HIV-1.BAL-infected PM1 Cells (A) or HIV-1.Rf-infected H9 cells (B) were 
cultured in EVR or TF-EVD medium conditions. Virus was collected at 7 days post 
infection and pelleted at 100,000xg for 2 hours. Pellet was diluted at 4 concentrations 
(shown on x-axis) in PBS and used to inoculate TZM/BL cells containing luciferase 
under the control of HIV LTR. After overnight incubation, an increase in luciferase 
activity was observed in the cells cultured with virus originating from TF-EVD medium 
compared with EVR medium at all concentrations. ****=p<0.0001, ***=p<.005, two-
way ANOVA with Sidak’s multiple comparison test of three biological repeats. C,D) 
show the  average, including the individual experiments shown in A and B, for three 
independent experiments of at least 4 biological replicates for both HIV-BAL and HIV-
RF. ****=p<0.0001, **=p<.01, two-way ANOVA with Sidak’s multiple comparison 
test. E,F) HIV-1.BAL and RF harvested from cells grown in replete media and 
subsequently added to TZM/BL cells grown in either condition demonstrates the same 
phenomenon. ****=p<0.0001, **=p<.01, two-way ANOVA with Sidak’s multiple 
comparison test of three biological repeats. 
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Figure 12. Increased infectivity of virus produced under EVD conditions from PM1 
(A) and H9 cells (B), as assessed by TZM-BL luciferase reporter cells. Infectivity is at 
least 2 fold hiigher for HIV-1.Rf at all viral inputs except 6.25 ng/p24 when averaged 




























































Figure 13. EVD conditions alter cell surface markers and respiration. A) H9 cells 
and B) PM1 cells displayed increased expression of selected surface/adhesion proteins by 
flow cytometry when cultured in UC-EVD or TF-EVD medium for 7 days; 1=expression 
on cells cultured in EVR. C,D) Seahorse Respiration Assay of mitochondria of 
monocyte-derived macrophages grown in TF-EVD had significantly reduced basal and 
maximal respiration, as well as compromised ATP production and spare respiratory 
capacity. ****=p<0.001, *=p<.05, 2-way ANOVA with multiple comparison, Sidak test. 
Annotations in C) are adapted from the product materials (Agilent Technologies). 1 
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Figure 14. Little evidence for miRNA uptake from serum or serum-induced changes 
in miRNA expression. A) Unbiased hierarchical clustering demonstrates cell type-
dependent miRNA expression, but no indication of differences associated with TF-EVD 
medium conditions. B) A total of five miRNAs appeared to be less abundant in TF-EVD 
conditions by two-fold or more in just one of the cell types, with no consistent findings 
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Table 1. Gene Ontology Analysis reveals increased transcripts associated with lipid 
synthesis in EV-starved cells. 














Lipid metabolism 6 1 2.4E-03
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The initial stages of HIV-1 infection are characterized by unchecked viral 
replication, followed by a decrease in plasma viral levels due to the host immune 
response. Eventually, if left untreated, viral levels will rebound above this set point. Most 
people living with HIV are chronic progressors (CP), who will gradually lose immune 
function and succumb to secondary infections if untreated. In a minority of individuals, 
however, known as elite suppressors (ES), a viral set point is established below the limit 
of detection of standard clinical assays (<50 copies of HIV-1 RNA/mL of blood) and 
maintained for extended periods of time [183,184].  
While there have been significant advances in understanding how this viral 
control is achieved, the precise mechanisms have not been fully elucidated. For example, 
protection has been correlated to different elements involving HLA corresponding to 
MHC class I. Some ES have a CCR5 delta-32 gene deletion or have the HLA-B57 allele; 
the modification of the former conveys resistance to attachment of HIV-1, while the 
increased expression of the latter enhances cytotoxic T-lymphocyte response [185–190] . 
Others have single-nucleotide polymorphisms in genes like MX-2, which encodes for a 
protein whose expression levels are increased by interferon-a and blocks HIV-1 nuclear 
import [191,192]. These genetic elements are not the sole drivers of elite suppression, 
however. One category of molecule that remains incompletely understood in HIV-1 
latency and elite suppression is small RNA, including miRNA.  
miRNAs modulate and reflect numerous cellular functions in immune response 
and host-pathogen interactions [193–195]. Most cells release miRNAs into the 
extracellular space, contained within protein complexes that protect the RNA species 
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from degradation [23] and in some cases also packaged into extracellular vesicles (EVs). 
Their stability has led to consideration of miRNAs as possible biomarkers and therapies 
alike [196–199]. anti-miR-122 therapies have now entered the clinic for Hepatitis C virus 
therapies. Could similar strides be made in HIV-1 disease? 
Multiple studies indicate that miRNAs may modulate HIV-1 latency and 
contribute to protection in ES. Some studies focus on specific miRNAs in cell lines or 
primary cells infected with HIV-1 [59,200–205]. Huang, et al. reported that miR-28, -
125b, -150, -223 and -382 targeted the 3’ LTR of HIV-1 in CD4+ T-cells, suggesting a 
role in HIV-1 latency [60]. Houzet, et al. demonstrated that miR-92a, -133b, -138, -149, 
and -326 decreased HIV-infection by targeting HIV-1 RNA [206]. HIV-1-produced 
sRNA may contribute to infection [207,208]. Differential miRNA expression has also 
been reported in ES and in HIV-1 infection in PBMCs, CD4+ T-cells, CD8+ T-
lymphocytes, plasma, monocytes [209–214]. Our lab reported significant differential 
miRNA expression between PBMC of ES and HIV-1 untreated viremic individuals, 
including the first identification of miR-31 as a possible restriction factor for HIV-1 
[215].  
Despite evidence that miRNAs affect HIV-1 infection, to date, there have been no 
studies of miRNAs in specific T-cell subsets, comparing ES to CP and healthy control 
(HC) individuals. In this study, we profiled CD4+ and CD8+ Naïve, Central Memory and 
Effector Memory for a few reasons. First, specific subtypes of immune cells may contain 
unique patterns of miRNAs and certain miRNAs may contribute to cellular identity and 
functional development [213,216]. Second, memory T-cells are preferentially infected by 
HIV-1. Memory cells from ES individuals are quantitatively and qualitatively different 
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from those found in CP and healthy donors [183]. Third, levels of CD8+ activation are 
higher in anti-retroviral-treated (ART) CPs than ES individuals, even when viral loads in 
both are similarly undetectable [217]. Finally, cells derived from ES patients are known 
to resist cell death through pathways involving factors FOXO3a, STAT5 and Wnt, which 
include well-characterized miRNA co-regulators including miR-29, miR-21, miR-155, 
and miR-28 [215,217–220]. Importantly, this work allows us to follow up and 
specifically identify subsets responsible for the changes seen in our work in PBMCs. 
Here, we provide the first miRNA profile comparing T-lymphocyte subsets 
between healthy donors and ES patients, utilizing a novel, combinatorial isolation 
strategy to obtain the different subsets from whole blood.  In addition, we show specific 
miRNAs that not only distinguish ES from CP and healthy controls, but also that many of 
these expression differences are unique to a class of T-lymphocyte. Several of these 
miRNA species that are differentially expressed in this study, confirming findings from 
previous studies, including our own.  
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Materials and Methods 
Donors 
Eighteen total and sixteen unique control (biological duplicates collected at 
different time points of two individuals were also obtained), eight elite suppressor (ES), 
ten chronic progressor (CP) and three viremic controller (VC) donors contributed blood 
to this study. Controls were healthy, HIV-1-negative donors. The ESs consistently 
maintain a viral load below the limit of detection (50 copies/mL) and had a median CD4+ 
T-cell count of 694 cells/µL (range 447-1453 cells/µL) at the time of donation All blood 
was obtained from patients and healthy donors (HDs) after they provided written and 
informed consent and was handled as recommended by the Institutional Review Board of 
the Johns Hopkins University (JHU IRB #CR00011400, NA_00093758).  A full readout 
of donor characteristics, including sex, age, BMI and ART regimen (where applicable) 
can be found in Table 1. 
PBMC isolation and plasma separation 
Blood was collected into 60 mL syringes pre-loaded with 6 mL anticoagulant 
Acid Citrate Dextrose (ACD) (Sigma Aldrich, St. Louis, MO. Cat #: C382, multiple lots), 
or six 8.5 mL vacutainers pre-coated with ACD (BD, 366645). Whole blood was 
centrifuged within 30 minutes of draw at 1300 x g for 15 minutes at room temperature to 
pellet cells. Supernatant was subsequently centrifuged twice at 2500 x g for 15 minutes 
each at room temperature to produce platelet-poor plasma (PPP), which was aliquoted 
and frozen at -80˚C until later use.  
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Cell pellets were re-suspended and diluted 1:1 with 2% fetal bovine serum (FBS) 
(Atlanta Biologicals) in Dulbecco’s phosphate buffered saline (DPBS) without Ca2+ or 
Mg2+ (Gibco) and added to a Ficoll-Hypaque (GE) gradient in SepMate™-50 tubes 
(STEMCELL Technologies, Vancouver, BC, Canada Cat #: 15450) and centrifuged for 
10 minutes at 1200 × g at room temperature. Plasma and PBMC fractions were removed, 
washed in PBS+ 2% FBS, and pelleted at 300 × g for 8 minutes. Pellets from 5 tubes 
were combined by resuspension in 10 mL RBC lysis buffer (4.15 g NHCl, 0.5 g KHCO, 
0.15 g EDTA in 450mL H2O; pH adjusted to 7.2–7.3; volume adjusted to 500 mL and 
filter-sterilized); total volume was brought to 40 mL with RBC lysis buffer. After 
incubation at 37 °C for 5 mins, the suspension was centrifuged at 400 × g for 6 mins at 
room temperature. An aliquot of PBMC was used for flow cytometric characterization for 
downstream separation of cells. The remaining PBMC were set aside for T-cell subset 
isolation. 
 
T-cell subset isolation 
Whichever cell subset was observed to have lowest population percentage at the 
time of collection, as measured by flow cytometric evaluation of whole PBMC, was 
treated as the “experiment-limiting population.” In all cases, this was the CD8+CD45RA-
CCR7+ cell population (CD8+ Central Memory). Population percentage (of total 
lymphocytes) of each cell type was entered into a spreadsheet and a calculation to obtain 
the largest number of the rate limiting cell type was performed, based on total PBMC 
yield, and percentage of lymphocytes that were the experiment-limiting cell type. This 
calculation informed the proper ratio to use when aliquoting all PBMC at the appropriate 
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concentrations for initial immunomagnetic separation. An example spreadsheet is shown 
in Figure 1. Initially, PBMC were isolated into CD4+ and CD8+ categories by using 
EasySep™ Human CD4+ or CD8+ T Cell Isolation Kits (StemCell, Catalog #17952 and 
#17953). Success of isolation and determination for inclusion in the study was assessed 
by positive staining for CD4+ or CD8+ (depending on isolation) with a positive rate of 
greater than 90% on all gated singlet lymphocytes measured on a LSRFortessa (BD). 
CD4+ and CD8+ cells were subsequently aliquoted into different tubes and 
stained with either CD45RA and CCR7 antibodies or with CD45RO antibodies per 
manufacturer’s recommendations. Cells were incubated for 15 minutes with antibodies 
and then washed and re-pelleted, and finally re-suspended in a volume of 250 µL. Each 
sample was then sorted on an Aria II (BD), with the negatively staining fractions being 
collected (i.e., CD45RO- for collection of the Naïve population, and CD45RA-, CCR7+ 
and CCR7- fractions for collection of central memory and effector memory populations, 
respectively. The schematic for this strategy is outlined in Figure 1B. Total counts of 
cells sorted were recorded. Cell fractions were pelleted, lysed with 600 µL mirVana RNA 
lysis buffer (Ambion, Austin, Texas, USA), and frozen at -80°C until RNA purification. 
The following antibodies were used for all staining of PBMC surface markers: PE 
mouse anti-human CD197 (Clone: 150503, Cat # 560765), FITC mouse anti-human 
CD45RA (Clone: HI100, Cat # 561882), PerCP-Cy5.5 mouse anti-human CD45RO 
(Clone: UCHL1, Cat # 560607), APC-H7 mouse anti-human CD8 (Clone: SK1, Cat # 
560179), BV605 mouse anti-human CD4 (Clone: RPA-T4, Cat # 562658). All antibodies 
were source from Becton Dickinson, NJ, USA. 
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RNA isolation and quality control 
RNA was isolated from all samples using a blinded, randomized distribution of all 
samples into batches of 18 to avoid batch effects and the potential influence of slight 
differences in RNA isolation. RNA was isolated in pre-determined batches (designed to 
eliminate batch effect) from each of the following T-cell subsets for all donors included 
in the study: CD4+ Naïve (CD4+N), CD4+ Central Memory (CD4+CM), CD4+ Effector 
Memory (CD4+EM), CD8+ Naïve (CD8+N), CD8+ Central Memory (CD8+CM) and 
CD8+ Effector Memory (CD8+EM). Each sample was then evaluated for quality control. 
Randomization was performed by an un-blinded collaborator who was not performing 
initial analyses (JB). All cell types from each donor were isolated concurrently (total of 
6) and group size was 3, with each group containing either one healthy donor, one ES or 
VC and one CP or two HDs and one of either ES/VC or CP. Thawed samples were 
processed for total RNA isolation using the miRVana miRNA isolation kit (Ambion) and 
following the manufacturer's protocol, with final elution in 100 uL of RNAase free water. 
RNA concentration was measured by Qubit RNA HS according to manufacturer’s 
specifications (Cat # Q32855) Concentration and RNA profile were also measured by 
Agilent BioAnalyzer 2100 using the Agilent Small RNA Kit (Catalog #5067- 1548). 
Subsequently, verification of RNA presence was performed by measuring the expression 
of several small RNAs, including miR-125b, cel-miR-39 and miR-16, with individual 
TaqMan miRNA assays, using a uniform input of 2 µL RNA (Applied Biosystems/Life 




Custom Human TaqMan® OpenArray® Human MicroRNA chips were prepared 
for cell and plasma profiling. The panel was designed to detect 96 unique miRNA 
sequences that have been found in the cells of interest and, in several cases, have been 
reported in association with HIV infection and disease. All assays were previously 
validated with artificial miRNA templates by the manufacturer. 2 µL of RNA was used as 
the input for reverse transcription using MegaPlex stem-loop primer pools, following the 
Life Technologies OpenArray protocol modification for low-concentration samples. 
Pre-amplification was done with MegaPlex pre-amp primer pools. Diluted pre-amp 
products were loaded onto the OpenArray chips by Accufill robot, following the standard 
protocols (Life Technologies part number 4461306 Rev. B). Real time quantitative PCR 
was performed with a QuantStudio 12K Flex Real-Time PCR System (Johns Hopkins 
DNA Analysis Facility), and data were collected with the manufacturer's SDS software. 
RQ Manager software (Applied Biosystems) was used to process the array data. The 
technical manual of the source code for the TaqMan OpenArray MicroRNA Panels are 
available at: https://tools.thermofisher.com/content/sfs/manuals/cms_092509.pdf  
 
Individual RT-qPCR Assays 
TaqMan miRNA assays (Applied Biosystems/Life Technologies) were performed 
according to the manufacturer's protocol and as previously described [215] with either 
reverse-transcribed or reverse-transcribed and pre-amplified samples. The small RNAs 
assayed were cel-mir-39, miRs -16, and -125b. 
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Data analysis and statistical methods 
We removed 9 out of 288 samples run across all chips, those of which had fewer 
than 60 miRNAs detected in the OpenArray run. Then, we removed any samples that 
were not a part of this study but were run at the same time. This generated one cohesive 
data set that included data from all CD4+ Central Memory, CD4+ Effector Memory, 
CD4+ Naïve, CD8+ Central Memory, CD8+ Effector Memory, CD8+ Naïve cells and an 
RNA cell control sample, which was a pool of RNA derived from CD4+ Naïve cells from 
7 different HDs. The RNA control sample aided in visualizing any potential batch effect. 
Next, the data was filtered to keep the 85 miRNAs that had an AmpScore ≥ 1.2 and at 
least 60% of amplifications present. Then, the cycle threshold (Ct) score was set to 40, if 
the Ct score for any miRNA in any sample was “Undetermined,” the AmpScore was < 
1.2, or if the Ct score was > 37. Subsequently, these missing data points (Ct = 40) were 
imputed (Bioconductor package “Non-detects”) including the control sample, which had 
been run on each chip. Finally, delta-delta Ct (ΔΔCt) analysis was performed, with 
normalization to a set of 4 stable miRNAs: hsa-miR-103, hsa-miR-25, mmu-miR-93 and 
hsa-miR-142-5p. The stable miRNAs were selected using a consensus between the top 10 
most stable miRNAs ranked by NormFinder and geNorm, as implemented in 
Bioconductor package NormqPCR. Differential expression analysis was performed by 
applying a Student’s t-test to the normalized Ct values and the p-values were adjusted for 
multiple testing by controlling the false discovery rate (FDR) according to the method of 
Benjamini and Hochberg. A miRNA was considered to be differentially expressed if the 
adjusted p-value was ≤ 0.1 Results were not dependent on this normalization method, as 
established by investigations of alternative normalization methods, including geometric 
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mean, and quantile normalization. Figures and tables were prepared using Microsoft 
Excel and Word, GraphPad Prism, MultiExperiment Viewer, Adobe Photoshop and 
Illustrator, and FlowJo. 
Ethics Statement 
Approval for all studies was granted by the Johns Hopkins Institutional Review 
Board. All study participants provided informed consent in writing. 
 
Results 
A novel combinatorial method to isolate specific T-cell subsets from whole PBMC and 
study cohort demographics 
While the primary goal of our study was to identify miRNA signatures of elite 
suppression in different T-cell subsets, an added benefit was the ability to identify 
miRNA signatures of specific T-cells in healthy individuals. To do this, whole blood was 
obtained from a total for 37 unique individuals, for 39 total samples: eighteen total 
samples from sixteen unique healthy individuals, eight samples from known elite 
suppressors (ES), ten from chronic progressors (CP), and three from viremic controllers 
(VC). Demographics of the study cohort are shown in Table 1. To evaluate miRNA 
expression in the relevant T-cell subsets, we first needed to ensure that we could conduct 
downstream RT-qPCR by determining the lowest number of starting cells detectable by 
quality control (QC) methods prior to RNA isolation. We determined the limit to be 
approximately 20,000 cells (Figure 2A, B). We then used a novel combinatorial method 
of T-cell subset isolation, involving negative immunomagnetic separation to isolate 
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CD4+ and CD8+ T-cells, followed by FACS using a negatively-based gating strategy, as 
outlined in Figure 3A and 3B and in the methods section. For all CD4+ subsets, cell 
count medians were significantly lower across all patients, while total CD8+ lymphocyte 
count was increased (Figure 4B, C). Final cell counts for each cell type, separated by 
healthy and infected were obtained following sorting (Figure 5). Isolating cells using this 
strategy allowed for very precise acquisition of the different subsets with generating as 
little stimulation as possible, ensuring the downstream data were as close to in vivo 
expression levels as feasible. Some RNA levels of some samples were below the level of 
detection by both Qubit and BioAnalyzer, however. We tested whether performing 
downstream assay by volume input rather than RNA input would influence expression 
data. Starting cell count correlated with RNA concentration determined by Qubit but not 
by BioAnalyzer (Figure 6A, B). In addition, no correlation between starting cell count 
and raw Ct value or pre-amplified RT product was appreciated when comparing Ct 
values via OpenArray for either miR-125b or miR-16 (Figure 6C). These results provided 
satisfactory data to confirm the viability of our novel combinatiorial approach to T-cell 
subset isolation and thus to proceed with OpenArray profiling assessment.  
 
OpenArray miRNA profiling distinguishes Naïve and Individual Memory Cell subsets 
from each other in healthy individuals 
Many recent studies, including from our own lab, have examined the sensitivity 
and specificity of different miRNA quantitation platforms. The OpenArray system has 
the sensitivity required to detect inadvertent sample swapping during processing 
[215,223]. The OpenArray platform employs reverse transcription, pre-amplification, and 
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quantitative real-time polymerase chain reaction (qPCR) using extremely low amounts of 
pre-amplified material to quantitate even low-abundance miRNAs with high sensitivity. 
For this study, we designed a custom chip that allowed us to profile almost 100 different 
features, which were carefully selected miRNA species based on previous ES profiling 
done in our lab and others, as well as based on previous studies indicating miRNA 
species importance in T-cell proliferation.  
After normalizing the data against the consensus most stable miRNAs, hsa-miR-
103, hsa-miR-25, mmu-miR-93 and hsa-miR-142-5p, we examined all healthy samples 
from all cell types separately from infected samples. This separation allowed us to 
examine the T-cell specific miRnome across all miRNAs. Rather than the expected 
hierarchical clustering by CD4+ or CD8+ phenotype, our data show that miRNA profiles 
are extremely similar between all Naïve cells as well as each of the Effector and Central 
Memory subsets (Figure 7). This trend was even more apparent when clustering only the 
significantly differentially expressed miRNA (Figure 8). In addition, we found that many 
miRNAs are differentially expressed in specific subsets relative to others.  
 
For the purposes of this analysis, we only included miRNAs whose expression 
level was at least one full deltaCt different from others, because this difference represents 
one full qPCR cycle. Naïve cells, regardless of CD4+ or CD8+ phenotype, showed the 
most instances of differential expression relative to memory cells, with miR-328, miR-
193b, miR-20a and miR-31, miR-342-3p, miR-125b and miR-181a being downregulated 
(Figure 9A), and miR-24, miR-146a, miR-21 and miR-27a being upregulated (Figure 
9B). Both Central Memory and Effector Memory cells had much fewer instances that 
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separated them from the other memory cell type and Naïve cells. miR-196b and miR-126 
appeared upregulated relative to both Effector Memory and Naïve cells (Figure 10A), 
while miR-150 was upregulated in Effector Memory cells relative to Central Memory and 
Naïve cells. These results not only represent the first T-cell subset-specific miRNA 
profiling but also demonstrate a surprising and novel miRNA phenotype that 
differentiates readily between Naïve and Memory cells in healthy individuals. 
 
OpenArray miRNA profiling reveals cell-type specific differential expression of miRNAs 
distinguishing between Healthy and Infected individuals 
Having evaluated the miRNA expression profiles of the T-cells in healthy 
individuals, we next evaluated expression difference within cell types between our 
healthy controls and all infected individuals. To accomplish this, we performed 
downstream analysis on the same normalized OpenArray data. Many miRNAs were 
differentially downregulated or upregulated within in each cell type. For Naïve cells, 
miR-9 was upregulated three-to-four-fold in CD4+ and CD8+ cells from the infected 
cohort relative to the healthy donors , while miR-155 was upregulated two-fold in CD8+ 
Naïve cells (Figure 11A, B). 
Interestingly, in CD4+ Central Memory cells, no miRs were upregulated and only 
miR-196b was downregulated, at more than two-fold (Figure 12A). In contrast, in CD8+ 
Central Memory cells, miR-196b was upregulated almost two-fold in infected samples, 
while miR-28-3p was upregulated almost four-fold (Figure 7B). miR-23a and miR-21 
were also significantly upregulated in the infected cohort, but at a rate of about 1.5-fold, 
equivalent to less than one qPCR cycle on average.  
	 104	
Finally, in Effector Memory cells, all miRNAs were downregulated in both CD4+ 
and CD8+ cells (Figure 13). miR-193b was significantly downregulated by almost four-
fold in both types, while miR-363, -125b, -31 and 196b were downregulated in CD4+ 
cells (Figure 12A). miR-363 had the largest relative difference, at approximately 40-fold. 
miR-146b-3p was also downregulated at a rate of four-fold in CD8+ EM T-cells (Figure 
13B).  
 
OpenArray miRNA profiling reveals cell-type specific differential expression of miRNAs 
distinguishing between Healthy, ES, and CP individuals 
To determine if the changes observed between the healthy and infected 
populations were more global or primarily driven by mechanisms found in ES or CP 
individuals, we examined the normalized data by comparing the relative expression of 
each population.  
The greatest number of differentially expressed miRNAs, contrary to the pattern 
in the healthy versus infected comparison, was observed in the Naïve cells. Differentially 
expressed miRNAs in ES individuals relative to healthy controls were upregulated 
exclusively in CD4+ and CD8+ Naïve cells (Figure 14A, 15A), with miR-9 and miR-21 
upregulated more than two-fold in both cell types, with miR-9 showing the greats 
upregulation of almost 10-fold in CD4+ cells. In CD8+ Naïve T-cells, other species were 
differentially upregulated in ES individuals compared to healthy controls as well, 
including miR-132 (3.4-fold), -15a (2-fold), -155 (2.1-fold), and -23a (1.9-fold) (Figure 
15A). miR-155 and miR-23a were also similarly upregulated in CP individuals compared 
to healthy controls. miR-335 and 146b-5p were downregulated 2.2- and 1.8-fold, 
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respectively (15B). miR-197 was the lone downregulated miRNA in CD4+ Naïve T-cells, 
but notably in CP relative to the control.  
As for the Central Memory cells, fewer differentially expressed species were 
found than in the Naïve cell comparison. Additionally, more differences in miRNA 
expression in CP versus control individuals and CP versus ES individuals were present. 
Importantly, miR-196b, was almost 3-fold downregulated in CP individuals compared to 
controls in CD4+ CM (Figure 16B). This result was especially striking when compared to 
the 2-fold upregulation between healthy and all infected samples. However, mir-196b 
was still upregulated by approximately 2-fold in CD8+ CM from ES individuals (Figure 
16C). miR-186 was also downregulated in CD4+ CM T-cells in CP relative to control, 
but the change was only about 1.5-fold. (Figure 16B). miR-19a, -23a were almost 2-fold 
upregulated in CP relative to control in CD8+ CM T-cells, while let-7b was upregulated 
in CP relative to both control and ES (Figure 16D). Finally, miRNA species which were 
significantly upregulated in ES compared to healthy controls but less than 2-fold were 
miR-103, miR-125a-5p, while let-7g and miR-320 were upregulated relative to CP 
(Figure 16A).  
Finally, in the Effector Memory cells, most changes were observed either in CP 
individuals relative to the healthy controls or between CP and ES individuals. All miRNA 
that were differentially expressed in CD4+ EM were downregulated, with significant 
downregulation calculated in miR-363, -31, -31*, -193b, and --196b and -146b-3p 
(Figure 17A). The largest relative differences were observed in miR-363, at almost 50-
fold downregulation. For CD8+ EM, miR-19a, -16 and -195 were all approximately 2-
fold higher in ES than CP individuals, although no significant differences were 
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appreciated between healthy controls and ES individuals (Figure 17B). miR-193b and -
146b-3p were downregulated almost 4-fold, with -193b also downregulated in ES 
individuals relative to the healthy controls (Figure 17C). 
 
Discussion 
We present here a comprehensive examination of the miRNA profile in T-cell 
subsets in multiple contexts. We show, for the first time, a miRNA profile for CD4+ and 
CD8+ Naïve, Central Memory, and Effector Memory T-cells in a cohort of healthy 
individuals. Using a novel combinatorial isolation strategy, we were able to isolate 
sufficient quantities of each cell type for downstream assessment of miRNA expression. 
The profiling data demonstrate that miRNA expression in healthy individuals appears to 
be driven primarily by cell sub-type – i.e., Central Memory, Effector Memory, or Naïve, 
rather than the CD4+ or CD8+ phenotype designation. Importantly, several miRNA 
known to be involved in T-cell activation or modulation or involved in HIV-1 latency 
were here differentially upregulated or downregulated in Naïve cells: miR-181a 
[224,225], -31 [215,226,227], 125b, -21 [228,229], -24 [230], -146a [194,231,232] and -
20a [233–235]. The clustering of these miRNA revealed unique miRNA profiles for 
Memory and Naïve cells.  
Of these differentially expressed species in healthy populations, several were also 
differentially expressed when comparing healthy individuals to infected individuals: mir-
196b, -193b, -31, 125b, and -21, but some of the expression differences occurred in 
different cell types. For example, in our intra-cell type comparison in healthy individuals, 
miR-125b and -193b were downregulated in CD4+ Naïve cells in healthy patients, but 
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these two miRNAs were specifically downregulated in CD4+ Effector Memory cells in 
infected individuals compared to healthy individuals. This finding improves confidence 
in our data, demonstrating that more general findings are not driven by huge differences 
in other components of the data.  
One miRNA of potential importance is miR-9, which was significantly 
upregulated in Naïve cells across all infected individuals, a phenotype subsequently 
shown to be driven by ES individuals. miR-9 has previously been shown to be 
upregulated in viremic individuals and to have a significant role in enhancing IL-2 
production in Naïve T-cells [236,237], but it is more commonly associated with 
upregulated in the basal ganglial cells in SIV-infected macaques. In addition, miR-9 was 
recently shown to mediate microglial migration when associated with extracellular 
vesicles secreted from cells simulated by HIV Tat [238]. There are two potential 
implications of miR-9 enriched expression in Naïve cells of ES individuals: 1) without a 
true viremic population for comparison (although the VCs included were on par or 
slightly lower in expression), it may be that the cytokine stimulation induced by miR-9 is 
beneficial in ES individuals, and 2) miR-9 upregulation may have anti-HIV-1 properties 
that outweigh any negative effects that occur as a result of increased inflammatory 
cytokine release. Further work to characterize the potential anti-HIV-1 properties of miR-
9 is warranted, and could provide insight into the elite suppression mechanism.  
Observed downregulation of miR-193b and -196b in Memory Cells of ES 
individuals is an important addition to the canon of miRNAs differentially expressed in 
ES individuals. A recent study by Wang et al highlighted the importance of miR-196b in 
vitro as a potential latency activator, and increased expression of miR-193b has now been 
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shown to be associated with liver damage in HIV-1 infected individuals [205,239]. These 
findings warrant further investigation into their precise mechanism and involvement in 
HIV-1 infection. 
Another important aspect of a profiling study, such as this one, is the ability to 
compare miRNA species differential expression relative to other similarly designed 
studies. While this study is the first of its kind to look at miRNA profiles of specific T-
cell subsets in ES individuals, many of the differentially expressed species are not 
unique. For example, in previous work from our laboratory, miR-155 was upregulated in 
ES individuals — this study confirms that finding but attributes the change specifically to 
CD8+ Naïve cells. We also saw changes in miR-155, miR-31, miR-21 and the let-7 
family, which were all found on the PBMC level. Obtaining confirmation of differential 
expression of the same miRNAs in completely different populations also lends significant 
credibility to the profiling data. 
Finally, as mentioned in the introduction, several miRNA, such as miR-21, -155, -
28, and -29a are important co-regulators of pathways involving FOXO3a, STAT5 and 
Wnt, which have been shown to be involved in resisting cell death in ES individuals or 
influencing latency. That they are shown to be upregulated in Naïve and Effector memory 
cells, reveals potential cell specific roles in the modulation of different pathways 
involved in cellular resistance to HIV-1 infection. 
One of the key limitations of this study is the lack of access to a viremic 
population, because these individuals are increasingly rare in the general population. 
Because most CP individuals receive ART treatment regularly, it is not surprising to see a 
dearth of differentially expressed miRNA between CP and controls. However, the 
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inclusion of this population in the study does allow for greater appreciation of differences 
between ES and control individuals. Also, in some instances, any differences between ES 
and CP individuals might be explained by direct role of ART in cellular processes in the 
face of HIV-1 infection, such as mir-16 or miR-19a in CD8+ EM or miR-103 in CD4+ 
CM. 
This profiling study highlights numerous miRNAs species that are differentially 
express in ES patients relative to healthy controls, some of which have potential roles in 
innate antiviral cellular response. Although this is not an exhaustive study, the miRNA 
evaluated here represent many of the most common miRNAs altered in the context of 
HIV-1 infection or are involved in T-cell proliferation or viability. Importantly, we 
highlight key expression differences of many miRNA species in healthy individuals, 
establishing a highly specific miRnome for these T-cell subsets. Our hope is that these 
data, in combination with the results showing up and downregulation of miRNAs in ES 
relative to our control individuals will continue to fuel investigations into biomarker 
development and evaluation of combinatorial small RNA-based alternative therapies for 





Figure 1. Example table for determining the appropriate volume for separating 
whole, FACS profiled, PBMC for downstream immunomagnetic isolation and 
FACS sorting. (A) allows for input of the percentages as calculated by initial FACS 
analysis of whole PBMC (Orange boxes), while (B) outputs the theoretical number of 
each desired T-cell subset based on the initial approximate count of total PBMC isolated 
by Ficoll separation. The Green boxes in A are the final volumes needed prior to the 




Figure 2. The threshold of detection of RNA in a sample is compromised at 5000 
starting cells. (A) Use of the readout from the Agilent Bioanalyzer 2100 demonstrates a 
linear relationship between the measured small RNA concentration corresponding to the 
number of starting cells used for analysis. (B) when the miRNA to small RNA ratio is 
calculated, apparent miRNA species become undetectable at 5000 cells, although they are 
still highly detectable at 50000 cells. 
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Figure 3. Experimental design and FACS sorting gating strategy. Using a 
combinatorial approach, PBMC are first separated into CD4+ and CD8+ populations 
using immunomagnetic negative isolation, then are separated into pertinent T-cell subsets 
using a negative staining approach in combination with FACS sorting (A). FACS gating 
strategy for already immunomagnetic purified populations of CD4+ and CD8+ T-cells is 



















Figure 4. Population frequencies of total CD4+ and CD8+ Lymphocytes as well as 
all CD4+ T-cell subsets are altered in infected donors relative to healthy controls. 
(A) Schematic for FACS analysis of relative lymphocyte subset abundance. (B) Relative 
abundance of different T-cell subsets is consistent between healthy and infected 
individuals, with CD8+ Central Memory cells the lowest in population percentage 
(Median less than 1% of all lymphocytes in both populations). (C) When relative 
percentages of all CD4+ lymphocytes and each of the three studied subsets are compared 
between groups, there is a significant decrease in patients for all cell types. CD8+ 
Lymphocytes are more abundant in patient samples. Significance in (B) was assessed by 
a Mann-Whitney t-test. Asterisks represent p-values: * = p < 0.05; ** = p < 0.01, **** = 














Figure 5. Cell yields for each T-cell subset included in the study. The median cell 
yield for each T-cell subset is represented by the colored bar, with 57,000 cells for 
healthy individuals and 78,000 for infected patients in CD8+ Central Memory cells, well 







Figure 6. Cell Concentration prior to RNA isolation correlates with RNA 
concentrated measured by Qubit but does not impact OpenArray readout data. 
There is a correlation between cell number in samples prior to RNA isolation to measured 
RNA concentration by Qubit (A), but the correlation is not apparent on BioAnalyzer 
evaluation (B). When pre-amplified material initial loaded by volume (2uL) for the 
Reverse Trasncription step is measured on the OpenArray qPCR platform (C), no 
correlation is appreciated in either miR-16 or miR-125b. 
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Figure 7. Hierarchical Clustering of OpenArray data: all normalized data inhealthy 
individuals. Targeted miRNA profiles were determined using the OpenArray platform. 
Hierarchical clustering of samples and features (Pearson correlation, average linkage) of 
data, normalized by approach as described in the methods. Abundance scale: red (high) to 


















Figure 8. Hierarchical Clustering of OpenArray data: significant differentially 
expressed miRNA by cell type in healthy individuals. Targeted miRNA profiles were 
determined using the OpenArray platform. Hierarchical clustering of samples and 
features (Pearson correlation, average linkage) of data, normalized by approach as 
described in the methods. Significance was assessed by Kruskal Wallis test followed by 
Dunn’s multiple comparison test, using the absolute distance of normalized expression 



































Figure 9. Individual miRNA OpenArray profiling results in healthy individuals: 
Naïve cells. The predominant number of miRNAs with differential expression occurred 
in Naïve cells relative to both types of memory cells. Downregulated (A) and upregulated 
(B) miRNAs in Naïve cells were identified from the deltaCt normalized data. Only 
miRNA for which the deltaCt was greater than 1 were included as significance. 
Significance was assessed by Dunn’s multiple comparison test, using the absolute 
distance of one cell type‘s mean expression value from another. Bar represents median 
expression value. Asterisks represent p values: * = p < 0.05; ** = p < 0.01, *** = p < 






Figure 10. Individual miRNA OpenArray profiling results in healthy individuals: 
other cell types. Upregulated miRNAs (A) and (B) were observed in Central Memory 
cells relative to the other cell types. Single instances of downregulation (B) and 
upregulation (C) were observed in Effector Memory cells. Only miRNA for which the 
deltaCt was greater than 1 were included as significance. Significance was assessed by 
Dunn’s multiple comparison test, using the absolute distance of one cell type‘s mean 
expression value from another. Bar represents median expression value. Asterisks 




Figure 11. OpenArray profiling results in Naïve cells comparing healthy donor to 
infected donor samples. hsa-miR-9 is upregulated in infected individuals more than 3 
fold in both CD4+ (A) and CD8+ (B) Naïve T-cells, while miR-155 was 2-fold 
upregulated in CD8+ Naive T-cells. No miRNA species were downregulated in infected 
individuals relative to healthy controls. Fold difference is relative to global expression of 
the 4 stable miRNAs as outlined in the methods section. X-axis scale is shown in log(2). 
Bar represents median expression value. Significance was assessed by a Mann-Whitney t-







Figure 12. OpenArray profiling results in Central Memory cells comparing healthy 
donor to infected donor samples. hsa-miR-196 is downregulated in infected individuals 
more than 3 fold in CD4+ (A) CM T-cells, but upregulated almost 2-fold in CD8+ T-
cells. miR–28-3p (almost 4-fold), -23a and -21 are about 2-fold upregulated in infected 
individual. Relative expression is relative to global expression of the 4 stable miRNAs as 
outlined in the methods section. X-axis scale is shown in log(2). Bar represents median 
expression value. Significance was assessed by a Mann-Whitney t-test. Asterisks 




Figure 13 OpenArray profiling results in Effector Memory cells comparing healthy 
donor to infected donor samples. hsa-miR-193b is downregulated in infected 
individuals more than 2-fold in both CD4+ (A) and CD8+ (B) EM T-cells. Additionally, 
miRs-363, -125b, -196b, and -31 are all downregulated about 2-fold in infected 
individuals in CD4+ (A) cells, while miR-146b-3p is also downregulated in CD8+ cells 
(B). Fold change is relative to global expression of the 4 stable miRNAs as outlined in 
the methods section. X-axis scale is shown in log(2). Bar represents median expression 
value. Significance was assessed by a Mann-Whitney t-test. Asterisks represent p-values: 














Figure 14. OpenArray profiling results in CD4+ Naïve cells comparing healthy 
donor to Elite Suppressor and Chronic Progressor donor samples. Most differentially 
expressed miRNAs are upregulated in CD4+ (A) Naive T-cells of ES. Naive cells from 
CPs showed downregulated differential expression in miR-197 (B). Fold change is 
relative to global expression of the 4 stable miRNAs as outlined in the methods section. 
X-axis scale is shown in log(2). Significance was assessed by Kruskal-Wallis test 
followed by Dunn’s multiple comparison test, using the absolute distance of one cell 
type‘s normalized mean expression value from another. Bar represents median expression 
value. VC are shown for comparison and not included in statistical calculations. Asterisks 















Figure 15. OpenArray profiling results in CD8+ Naïve T-cells comparing healthy 
donor to Elite Suppressor and Chronic Progressor donor samples. Most differentially 
expressed miRNAs are upregulated in CD8+ (A) Naive T-cells of ES. Naive cells from 
CPs showed differential expression in miR-155 and -23a (upregulated) in CD8+ Naive T-
cells (A). Both mir-335 and miR-146b–3p were downregulated (B). Fold change is 
relative to global expression of the 4 stable miRNAs as outlined in the methods section. 
X-axis scale is shown in log(2). Significance was assessed by Kruskal-Wallis test 
followed by Dunn’s multiple comparison test, using the absolute distance of one cell 
type‘s normalized mean expression value from another. Bar represents median expression 
value. VC are shown for comparison and not included in statistical calculations. Asterisks 
represent p-values: * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
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Figure 16. OpenArray profiling results in Central Memory cells comparing healthy 
donor to Elite Suppressor and Chronic Progressor donor samples. Most differentially 
expressed miRNAs are upregulated in both CD4+ (A) and CD8+ (C) CM T-cells of ES 
relative to controls. miR-186 and miR-196b were downregulated in CD4+ EM T-cells in 
CP relative to control (B). miR-19a, -23a were upregulated in CP relative to control and 
ES in CD8+ CM T-cells, while let-7b was upregulated in CP relative to both control and 
ES (D). Fold change is relative to global expression of the 4 stable miRNAs as outlined 
in the methods section. X-axis scale is shown in log(2). Significance was assessed by 
Kruskal-Wallis test followed by Dunn’s multiple comparison test, using the absolute 
distance of one cell type‘s normalized mean expression value from another. Bar 
represents median expression value. VC are shown for comparison and not included in 






Figure 17. OpenArray profiling results in Effector Memory cells comparing healthy 
donor to Elite Suppressor and Chronic Progressor donor samples. All differentially 
expressed miRNAs are downregulated in both CD4+ (A) EMT-cells of ES reltaive to 
controls, with miR-31 downregulated in CP relative to control and ES. miR-19a, miR-16 
and miR-195 were upregulated in EM cells from ES relative to CP in CD8+ EM (B). 
miR-193b and miR-146-3p were downregulated in CP relative to control in CD8+ EM 
(C), with 193b also downregulated in ES relative to control. Fold change is relative to 
global expression of the 4 stable miRNAs as outlined in the methods section. X-axis scale 
is shown in log(2). Significance was assessed by Kruskal-Wallis test followed by Dunn’s 
multiple comparison test, using the absolute distance of one cell type‘s normalized mean 
expression value from another. Bar represents median expression value. VC are shown 
for comparison and not included in statistical calculationsAsterisks represent p-values: * 
= p < 0.05, ** = p < 0.01 
 


















































































Table 1. ID numbers and characteristics of 37 unique donors. (A) Healthy donors, (B) 
Patient Donors. Abbreviations for ART Regimen: TDF: tenofovir ; FTC: emtricitabine; 
RAL: raltegravir; EFV: efavirenz; ATV/r: atazanavir/low dose ritonavir ; 3TC: ; FPV/r: 
fosamprenavir/low dose ritonavir; DTG: dolutegravir; ABC: 

























Subject	Number Infection	Status Sex Viral	Load	(copies/mL) CD4+	T-cell	Count CD4+	T-cell	% ART	Regimen BMI BMI	Classification Age Age	Range
1 ES Female <50 554 48.8 Untreated 17.6 Underweight 59 55-59
2 CP Female <50 766 26.9 TDF,FTC,	RAL 27.8 Overweight 53 50-54
3 CP Male <50 737 34.5 EFV,	ATV/r 25 Normal 53 50-54
4 CP Male <50 415 44.8 EFV,	TDF,	3TC 25.2 Overweight 32 30-34
5 CP Male <50 948 24.8 ABC,3TC,	FPV/r 34.5 Obese 47 45-49
6 CP Male <50 860 35.8 3TC,	EFV,	RAL 25.8 Overweight 52 50-54
7 ES Female <50 676 39 Untreated 35.1 Obese 64 60-64
9 CP Male <50 722 40 DTG,	DRV/r 29.4 Overweight 49 45-49
10 CP Male <50 885 38.5 TDF,FTC,ELV/c 31.5 Obese 47 45-49
11 ES Male <50 1414 54.5 Untreated NA NA 54 50-54
12 ES Female <50 1149 47.1 Untreated 39 Obese 63 60-64
14 VC Male 748 856 35.5 Untreated 30 Obese 60 60-64
16 ES Male <50 597 42.4 Untreated 20.4 Normal 49 45-49
17 CP Male <50 1109 41 ABC,3TC,DTG 23.5 Normal 62 60-64
18 ES Female <50 711 39.6 Untreated 39.2 Obese 66 65	and	older
20 CP Male <50 642 NA ABC,	3TC,	RAL 27.7 Overweight 47 45-49
21 ES Male <50 447 19.1 Untreated 20.2 Normal 64 60-64
22 CP Male <50 995 32.5 ABC,3TC,DTG 29.9 Overweight 54 50-54
23 VC Female 98 1101 30.3 Untreated 44.2 Obese 45 45-49
24 VC Male <50 719 26.2 Untreated 28.3 Overweight 60 60-64

































































Despite decades of research dedicated to understanding the complexities of HIV-1 
interactions with the human immune system, a cure remains elusive. For this reason, 
scientists continue to learn as much as they can about the virus and how it affects all parts 
of the body. For our part, we utilized human disease models and in vitro culture to 
explore the interplay between HIV-1, EVs, and miRNA, ultimately leading to several 
insights into the complex relationship between host and retrovirus.  
As described in Chapter two, we explored the potential of EVs as biomarkers of 
viral suppression in the cervicovaginal compartment. We observed a decrease in EV 
numbers in reproductive tract disease (endometriosis) and in SIV-infected macaques. We 
performed functional studies in human macrophages after discovering that miR-186 was 
more abundant in the EVs obtained from the secretions of infected animals, and found 
evidence for its role as an HIV-1 restriction factor. Our hope is that by dedicating some 
of our efforts to studying SIV and EVs in the reproductive system, which happens to be a 
primary location of disease transmission in people, that we will lay the groundwork for 
others to further explore its complex immune capacity and perhaps discover vital 
biomarkers or restriction factors that may help in the development of new treatment 
strategies. 
 Chapter three of this dissertation addresses EVs and HIV-1 infection through a 
series of in vitro studies using EV-depleted serum in cell culture. Work by Eitan et al 
using  EV-depleted serum in cell culture demonstrated variable amounts of cell growth 
retardation and reduced viability of numerous cell lines including U87 glioblastoma, 
HEK-293T, HeLa, SY5Y human neuroblastoma, and N2a mouse neuroblastoma cell. 
Coupled with varying reports on the involvement of EVs in facilitating or hampering 
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HIV-1 infection [39,40,166,240], we felt it prudent to evaluate the impact of serum-
derived vesicles on in vitro HIV-1 infection. We described and presented data 
demonstrating that the depletion of EVs from cell culture conditions exacerbates primary 
HIV-1 infection, reactivates latent, integrated virus, and creates a more infectious virus. 
We were able to reverse this phenotype by adding back EVs derived from serum at 
various concentrations. The changes observed appear to be driven primarily by lipid 
pathways, though elucidation of the exact mechanism is needed. Furthermore, we added 
to a growing canon of literature suggesting that EVs in circulation protect against HIV-1 
infection. In future studies, we will perform add-back experiments using EVs derived 
from different cell lines to evaluate the impact of endogenous EVs on HIV infection. 
Although the miRNA data generated in this study showed minimal involvement of 
miRNAs, the panel examined was not exhaustive. We plan to investigate the entire small 
RNA response in this context through next-generation sequencing. It is not likely that 
there is a single silver bullet in the fight against HIV, but deciphering small pieces of the 
complex relationship may ultimately result in breakthroughs.  
 Finally, in chapter four, guided by previous studies of miRNA expression in 
PBMCs of ES and viremic individuals, we studied T-cell subsets with roles in combating 
HIV-1 infection. miRNA expression profiles of healthy controls, CP and ES, revealed 
robust clustering of Naïve, Central Memory and Effector Memory T-cells regardless of 
CD4+ or CD8+ phenotype or HIV-1 infection status. Perhaps the most intriguing 
observations, though, were the cell-specific expression differences we observed between 
the three cohorts – in Naïve cells almost all expression differences were elevated in ES 
relative to controls. In Memory cells, the differences were more variable as to whether 
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they were in CP or ES, and were variable in whether they were upregulated or 
downregulated. Specific miRNA like miR-9, -21, -31, and -155 were associated with 
specific T-cell types, and had previously been associated with ES at the PBMC level. 
Thus, by comparing miRNA expression in these same T-cells but instead evaluating for 
upregulation or downregulation of miRs between ES, CP and healthy individuals, we 
were able to build on ours and others work that indicates that miRNA play a significant 
role in the manifestation of HIV-1 suppression. We collected matched plasma from these 
individuals to study total and EV miRNA expression in ES relative to CP and HC. We 
hope that the miRNA profiles presented here will be helpful to others who study HIV-1 
elite suppression. 
The work included in this dissertation only scratches at the surface of the complex 
relationship between EVs and miRNA in the context of HIV-1 or SIV infection. It is our 
hope that the findings discussed here lay the groundwork for further studies in all areas 
explored here, both in our own lab and in others, that may eventually result in the 
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